PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 1
A PHASE 1B, RANDOMIZED, DOUBLE-BLIND (SPONSOR-OPEN), 
PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE 
SAFETY, TOLERABILITY, PHARMACODYNAMICS AND 
PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF-06865571 FOR 
2 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Investigational Product Number: PF-06865571 
Investigational Product Name: Not Applicable (N/A)
United States (US) Investigational 
New Drug (IND) Number:
European Clinical Trials 
Database (EudraCT) Number:N/A
Protocol Number: C2541005
Phase: 1bCCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 2Document History
Document Version D ate Summary of Changes and Rationale
Original protocol 27February 2018 N/A

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....7
LIST OF FIGURES ................................................................................................................ ...7
APPENDICES ..................................................................................................................... ......7
SCHEDULE OF AC TIVITIES..................................................................................................8
1. INTRODUCTION ...............................................................................................................1 1
1.1. Mechanism of Action/Indication.............................................................................111.2. Background .............................................................................................................11
1.2.1. Nonclinical Primar y Pharmaco logy............................................................12
1.2.1.1. In Vit ro Assays..........................................................................12
1.2.1.2. In Vivo Studies..........................................................................12
1.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................121.2.3. Summary of Toxicology Studies ................................................................131.2.4. Preliminary Summary of Clinical Experience............................................14
1.3. Study R ationale .......................................................................................................16
1.3.1. Study Design Rationale ..............................................................................16
1.3.1.1. Study P opulation .......................................................................18
1.3.2. Dose Rationale............................................................................................19
2. STUDY OBJECTIVES AND ENDPOINTS.......................................................................203. STUDY DESIGN................................................................................................................ .21
3.1. Study Ov erview.......................................................................................................21
4. SUBJECT ELIGIBILITY CRITERIA.................................................................................22
4.1. Inclusion Criteria.....................................................................................................22
4.2. Exclusion Criteria....................................................................................................234.3. Randomization Criteria ...........................................................................................274.4. Lifestyle Requirements ...........................................................................................27
4.4.1. Meals and Dietary Restrictions...................................................................274.4.2. Alcohol, Caffeine, and Tobacco .................................................................284.4.3. Activity .......................................................................................................294.4.4. Contraception..............................................................................................29
4.5. Sponsor’s Qualified Medical Personnel..................................................................30CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 45. STUDY TREATMENTS .....................................................................................................30
5.1. Allocation to Treatment
..........................................................................................30
5.2. Breaking the Blind
..................................................................................................31
5.3. Subject Compliance .................................................................................................32
5.4. I nvestigational Product Supplies .............................................................................32
5.4.1. Dosage Form and Packaging ......................................................................32
5.4.2. Preparation and Dispensing ........................................................................32
5.5. Administration .........................................................................................................32
5.6. I nvestigational Product Storage
..............................................................................33
5.7. I nvestigational Product Accountabilit y
...................................................................33
5.7.1. Destruction of Investigational Product Supplies ........................................34
5.8. Concomitant Treatments .........................................................................................34
5.8.1. Anti
-Hypertensive Medications ..................................................................34
5.8.2. L
ipid-Modify ing Medications ....................................................................34
5.8.3. Other Acceptable Concomitant Medications ..............................................35
5.8.4. Prohibited Concom itant Medications .........................................................35
5.9. Rescue Medication ..................................................................................................37
6. STUDY PROCEDURES
.....................................................................................................37
6.1. Proposed Chronology of Procedures .......................................................................37
6.2. Screening .................................................................................................................38
6.3. Study  Period ............................................................................................................38
6.4. Follow -
up ................................................................................................................39
6.5. Subject Withdrawal .................................................................................................39
7. ASSESSMENTS ..................................................................................................................41
7.1. Safet y
.......................................................................................................................41
7.1.1. L aboratory  Tests .........................................................................................41
7.1.2. Serum for Cy statin C ..................................................................................43
7.1.3. Phy sical Examinations ................................................................................43
7.1.4. Body  Weight ................................ ................................ ............................... 43
7.1.4.1. Adjustment of Caloric Intake to Ma intain Stable Body  
Weight ...............................................................................................44
7.1.5. Blood Pressure and Pulse Rate ................................ ................................ ...44

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 57.1.6. Electrocardiogram.......................................................................................44
7.2. Pharmacokinetics ....................................................................................................45
7.2.1. Plasma for Analysis of PF-06865571.........................................................45
7.5. Imaging Assessments ..............................................................................................49
7.5.2. Assessment of Liver Fat Using MRI-PDFF Acquisition and Analysis......49
7.5.3. Analysis of MRI-PDFF Images Including Determination of 
Eligib ility .........................................................................................................50
7.5.4. Management of Incidental Findings ...........................................................507.5.5. Post-hoc Analyses.......................................................................................51
7.6. Potential Cases of Acute Kidney Injury..................................................................517.7. Blood Volume .........................................................................................................52
8. ADVERSE EVENT REPORTING......................................................................................52
8.1. Requirements...........................................................................................................52
8.1.1. Additional Details on Recording Adverse Events on the CRF...................538.1.2. Eliciting Adverse Event Information..........................................................538.1.3. Withdrawal From the Study Due to Adverse Events (see also the 
Subject Withdrawal section)............................................................................53
8.1.4. Time Period for Collecting AE/SAE Information......................................54
8.1.4.1. Reporting SAEs to Pfizer Safety...............................................548.1.4.2. Recording Non-serious AEs and SAEs on the CRF .................54
8.1.5. Causality Assessment .................................................................................548.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities ..................55
8.2. Definitions............................................................................................................... 55
8.2.1. Adverse Events ...........................................................................................558.2.2. Abnormal Test Findings .............................................................................56CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 68.2.3. Serious Adverse Events ..............................................................................56
8.2.4. Hospitalization............................................................................................57
8.3. Severity Assessment................................................................................................588.4. Special Situations ....................................................................................................58
8.4.1. Potential Cases of Drug-Induced Liver Injury............................................588.4.2. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................60
8.4.2.1. Exposure During Pregnancy......................................................608.4.2.2. Exposure During Breastfeeding ................................................618.4.2.3. Occupational Exposure .............................................................61
8.4.3. Medication Errors .......................................................................................62
8.4.3.1. Medication Errors......................................................................62
9. DATA ANALYSIS/STATISTICAL METHODS...............................................................63
9.1. Sample Size Determination.....................................................................................639.2. Efficacy Analysis ....................................................................................................63
9.2.1. Analysis of the Primary Endpoint...............................................................63
9.3. Pharmacokinetic Analysis .......................................................................................64
9.3.1. Derivation of Pharmacokinetic Parameters ................................................64
9.6. Safety Analysis........................................................................................................65
9.6.1. Electrocardiogram Analysis........................................................................65
9.7. Interim An alysis ......................................................................................................66
9.8. Data Monitoring Committee ...................................................................................66
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................6611. DATA HANDLING AND RECORD KEEPING .............................................................67
11.1. Case Report Forms/Data Collection Tools/Electronic Data Record.....................6711.2. Record Retention...................................................................................................67
12. ETHICS..................................................................................................................... .........68
12.1. Institutional Review Board/Ethics Committee......................................................68
12.2. Ethical Conduct of the Study ................................................................................68CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 712.3. Subject I nformation and Consent ..........................................................................68
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................69
13. DEFI NITION OF EN D OF TRIAL ...................................................................................69
13.1.
End of Trial in the United States...........................................................................69
14. SPONSOR DI SCONTI NUATI ON CRITERIA ................................................................69
15. PUBLICATION OF S TUDY RESUL TS..........................................................................69
15.1. Communication of Results by  Pfizer ....................................................................69
15.2. Publications by  Investigators ................................................................................70
16. REFERENCES ..................................................................................................................72
LIST OF TABLES
Table 1. Overall Visit Schedule and L ist of Procedures .......................................................8
Table 2. Schedule of Activities 
–Study  Day s -1, 1, 7 & 14 ...............................................10
Table 3. Summary  of Plasma PF -06865571 PK Parameters Following Single Oral 
Doses in C2541001
...............................................................................................15
Table 4. Summary  of Preliminary  Steady  State (Day  14) Plasma PF -06865571 PK 
Parameters Fo
llowing Multiple Oral Doses in C2541002 ....................................16
Table 5. Predicted Stead y
-State PF -06865571 Exposures with Administration of 
Multiple Doses of PF -06865571 Under Fed Conditions ......................................20
Table 6. Clinical L aboratory  Tests .....................................................................................42
Table 7. Definition of Stead y State (Day 14) Plasma PK Parameters for 
PF
-06865571.........................................................................................................64
LIST OF FIGURES
Figure 1. Design of Study  C2541005 ...................................................................................21
APPENDICES
Appendix 1. Abbreviations ......................................................................................................74
Appendix 2. Strong CYP3A Inhibitors and Inducers* ............................................................78

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 8SCHEDULE OF ACTIVITIES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to Section 6 and Section 7 of the 
protocol for additional information on each procedure and assessment required for compliance with the protocol. The investigator  
may schedule visits (unplanned visits) in addition to those listed in the schedule of activities table, in order to conduct eval uations or 
assessments required to protect the well-being of the subject.
Table 1. Overall Visit Schedule and List of Procedures
Protocol Activity Screening Day -2 Study Day (all activities at 0H [prior to dosing] unless otherwise specified)aFollow-upb
Days Relative to Dosing on Day 1 Screen 1 Screen 2 Screen 3 -1 1 23456 78 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 V i s i t C o n t a c t
Visit 1 2 3 4 5 -
Informed consent & demography x
Outpatient visit (after ≥8H fast) x x
Adverse event monitoring x x → → →→→→→ →→ →→→→ →→→ xx x
Inpatient stay at CRU xc→ → →→→→→ →→ →→→→ →→→ x
Medical & medication history x x
Refer to  Tabl
Refer to  Tabl
Refer to  Tabl
Refer to  Tablxx
Review drug, alcohol/tobacco use x x x
Review prior or concomitant treatments x x x
Review contraception use x x xx
Physical examination (height at Screen 1 only)dxx x
Body weight x x x x xx
Triplicate, supine 12-lead ECGexx x xx
Single, supine vital signs assessmentexx x xx
Liver fat and stiffness (via FibroScan®)ffxx
Liver fat via MRI-PDFF acquisitionf,gxx x
Standardized meals/snackshx xxxxx x xxxx xx x
Administration of blinded IPixxxxx x xxxx x
Blood sampling for:
- Clinical laboratory tests and serum cystatin Cjxx x x x
- Serum FSH (females only), HIV, HepBsAg, 
HepBcAb, HCVAb testingx
- Ceruloplasmin, A1AT, HbA1c x
- PF-06865571 PKkxx x
- Serum TG x
- Plasma insulinjxx x xCCI
CCICCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 9Protocol Activity Screening Day -2 Study Day (all activities at 0H [prior to dosing] unless otherwise specified)aFollow-upb
Days Relative to Dosing on Day 1 Screen 1 Screen 2 Screen 3 -1 1 23456 78 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 V i s i t C o n t a c t
Visit 1 2 3 4 5 -
Urine sampling for:
- Urine drug test x
- Urinalysis (and microscopy, as appropriate) x x x xx
a. Day relative to start of dosing of blinded investigational product (Day 1).
b. Follow-up visit at 7-10 days following the last dose will be an  outpatient visit to the site, while follow-up contact at 28-35 days following the last dose may occur via a follow-
up phone call.  Phone call may be a visit if deemed necessary by the investigator.
c. Admission to CRU should occur prior to lunch on Day -2. 
d. Full physical exam at Screen 1 and at Day 15; otherwise, limited exam if findings during previous exam or new/open AEs, if appro priate, at investigator discretion.
e. Prior to AM dose.
f. After ≥8H fast at outpatient visits; scans on Days -2 & 15 to occur post overnight fast of ≥8H at approximately same clock time (ie, within a practical window ( ±2 hours) 
relative to clock time of the Screening visits).  
g. At Screen 3 visit after confirmation of allother eligibility.
h. Meals to be provided at approximately 0H, 4H, and 10H post AM dose and snack to be provided at approximately 12H post AM dose, as specified in Section 4.4.1 .  Day 16 
meal(s) are optional, according to clinical research unit (CRU) practice.
i. Dosing to occur with breakfast and snack, as specified in Section 4.4.1 .
k. PK samples to be collected prior to dose.CCICCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 10Table 2. Schedule of Activities – Study Days -1, 1, 7 & 14
[Procedures at 0H to be completed prior to dosing or similar clock time, in the case of Day -1]
Hours Relative to Dosing at 0Ha0 0 . 5 123468 1 0 1 2 1 4 1 6 1 8 2 4
Continued inpatient stay at CRU →→→→→→→→→→→→→→
Adverse event monitoring →→→→→→→→→→→→→→
Body weight x
Triplicate, supine 12-lead ECG x
Single, supine vital sign assessment x
Blinded IP administration (Days 1, 7 and 14 only) xbxc
Randomization (Day 1 only) x
Blood sampling for:
- Clinical laboratory tests and serum cystatin Cd(Days 1, 7, and 14 only) x
- PF-06865571 PK (Day 14 only) x x xxxxx x
- Serum triglycerides (Days -1, 1 and 14 only)dxfx xxxxxxxx
- Plasma insulind,gx
Urine sampling for:
- Urinalysis and microscopy, as appropriate (Days 1, 7, and 14 only) x
Mealsh
- Standardized meal x x x
- Snack x
a. On Day -1, nominal time to approximately match clock time of collection planned on Day 1 to permit time-matched comparison. 
b. Dosing expected to occur with breakfast.c. Dosing expected to occur with snack as specified in Section 4.4.1.
g. Insulin samples collected in triplicate on Day -1 and Day 14.  On Day 1 and Day 7, only 1 sample will be collected.
h. Meals/snacks to occur on all days while inpatient; identical meals/snacks on Days -2, -1, 1, 14, and 15.CCI
CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 111.INTRODUCTION
Diacy lglycerol acy ltransferases (DGATs) cataly ze the terminal step in trigly ceride (TG) 
synthesis; specifically , the esterification of a fatty  acid (FA) with diacy lglycerol (DAG) 
resulting in the formation of TG.1  In mammals, 2structurally  unrelated DGAT enzy mes 
(DGAT1 and DGAT2) have been characterized.  DGAT1 is highly  expressed in the intestine 
and play s a central role in fat absorption.2  DGAT2 is highly  expressed in liver and adipose.3  
In preclinical models, blockade of hepatic DGAT2 using antisense oligonucleotides results in 
both down- regulation of the expression of multiple genes encoding prote ins involved in 
lipogenesis and parallel induction in oxidative pathway s.4,5Thenet result of these changes is 
a decrease in the levels of hepatic DAG and TG lipid 
which, in turn, reduces hepatocy te lipid 
burden and decreases hepatic very  low densit y lipoprotein (VLDL) TG secretion.5,6  
PF-06865571 is an oral, small molecule DGA T2 inhibitor that is postulated to decrease 
hepatic TG s ynthesis and hepatic lipid burden in non -alcoholic fatty  liver disease (NAFLD) 
and non- alcoholic steatohepatitis (NASH).
The current study  is the first designed to eva luate the safet y, tolerability , pharmacokinetics 
(PK), andpharmacod ynamics (PD) following administration of repeated (up to 14 days) oral 
doses of PF -
06865571 in the fed state to adult subjects with NAFL D. 
1.1. Mechanism of Action/ Indication
PF-06865571 is an oral, small molecule DGAT2 inhib itor that is currently  being developed 
for the treatment of NASH.
1.2.Background 
NAFL D is estimated to affect at least 25% of the general population in Western countries, 
while the prevalence of NASH is estimated at 3 to 5%.7  NAFL D is strongly  associated with 
obesity , insulin resistance, hy pertension
,and d yslipidemia and is now regarded as the hepatic 
manifestation of metabolic sy ndrome.8  NAFL D describes a spectrum of liver conditions 
whose dominant feature is hepatic TG accumulation.9  NASH is diagnosed clinically  by liver 
biopsy  demonstrating steatosis, inflammation
,and ballooning of liver hepatocy tes, often with 
varying d egrees of fibrosis.  NASH progresses with increasing degrees of fibrosis, with 
cirrhosis and/or hepatocellular carcinoma developing in a subset of patients.10  Although the 
factors that promote TG deposition in the liver and transition from steatosis to NASH and 
cirrhosis in humans have not been clearl y defined, hepatic steatosis arises from an imbalance 
between TG acquisition and removal.11  Although there is a growin g body  of evidence that 
demonstrates the urgent need for therapies for NASH, there are no currently  approved 
therapies for the treatment of NASH.10
Hepatic TGs are derived from 3principal sources: de -novo lipogenesis (DNL), 
re-esterification from FA supplied by  the adipose, and dietary  intake.11  While the largest 
contribution to the hepatic TG pool appears to be derived from lipol ytic products originating 
in adipocy tes, the lipogenic pathway  play s an important role in the development of NAFLD 
and progression to NASH.12  The contribution of DNL to disease progression in NAFL D is 
supported by anal yzing the FAcomposition of T Gs in subjects with and without NAFL D.  
Data demonstrate an increased level of saturated FAs in those with NAFL D, implicating the 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 12DNL pathway as an important contributor to hepatic steatosis as saturated FAs represent the 
primary product of DNL.12  These findings are consistent with the increased inclusion of 
DNL-derived TGs in VLDL particles in NAFLD where 15% of TG produced originated from DNL compared to only 2 to 5% in normal subjects consuming a typical Western diet.
12  
Additionally, elevated rates of hepatic DNL have been reported to be a distinctive characteristic of NAFLD.
13  Human subjects with elevated liver fat showed a more than 
3-fold increase in the rate of hepatic DNL relative to subjects with normal liver fat, but no differences between the groups were detected in adipose free fatty acid (FFA) flux or in production of VLDL from FFAs.  Consequently, when comparing the absolute sources of FAs incorporated into VLDL-TG, elevated hepatic DNL was the only source significantly elevated in subjects with high liver fat.
13
Based on observations in nonclinical studies conducted with PF-06865571, it is hypothesized that DGAT2 inhibition will impact both physiological drivers contributing to NASH via direct inhibition of liver TG synthesis, as well as adaptive responses leading to reduction in hepatic DNL. 
1.2.1. Nonclinical Primary Pharmacology
1.2.1.1. In Vitro Assays
PF-06865571 is a potent and selective inhibitor of human DGAT2 (hDGAT2).  
 The selectivity of PF-06865571 for DGAT2 was supported 
by in vitro studies demonstrating >2000-fold selectivity by biochemical assessment versus related acyltransferases including recombinant human DGAT1 (hDGAT1), monoacylglycerol acyltransferase (MGAT)2 and MGAT3, as well as mouse MGAT1.   
 
 
1.2.1.2. In Vivo Studies
Following single dose administration, PF-06865571 demonstrates robust, dose-dependent 
reduction of plasma triacylglycerol in rats fed a high sucrose-diet.  In longer term studies in Western diet fed rats, PF-06865571 reduces both plasma triacylglycerol and hepatic lipid 
accumulation.  In line with the proposed mechanism of action, administration of
PF-06865571 in both sucrose and Western diet fed rats results in suppression of key genes involved in hepatic lipid metabolism, including the messenger ribonucleic acid (mRNA) expression of proprotein convertase subtilisin/kexin type 9 (PCSK9).  In these nonclinical models dosed with PF-06865571, PCSK9 mRNA was decreased relative to vehicle treated animals by 55% and 84% in the Western and sucrose-diet models, respectively.
1.2.2. Nonclinical Pharmacokinetics and Metabolism
Nonclinical data indicate that PF-06865571 has high passive permeability and is a substrate 
for multi-drug resistance protein 1 (MDR1, also known as P-glycoprotein or P-gp) and C
CICCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 13mouse breast cancer resistant protein ( mBCRP ) efflux transporters.  PF -06865571 was 
rapidly  absorbed in rat and moderatel y absorbed in the monkey with a mean oral 
bioavailability  of 31% and 48%, respectively . 
Urinary  excretion (rat and monkey ) of unchanged drug was  1%, while biliary  excretion of 
unchanged drug was <1% when assessed in bile duct cannulated rats.
PF-06865571 was moderately  bound to plasma proteins in rat, monkey , and human with 
average fraction unbound (fu) ranging from 0.213 to 0.419, and preferentially  distributes into 
plasma relative to blood with blood to plasma concentration ratio ranging between 0.659 and 
0.901.  The major clearance mechanism of PF -06865571 is predicted to be predominantly  by 
CYP3A mediated metabolism with minor contributions by  CYP2B6 and CYP2C19.  
There is no evidence of human -unique metabolites ,and all metabolites detected in human 
cryopreserved hepatocytes were also observed in the nonclinical toxicology species (rat and 
monkey ).  Reaction phen otyping studies indicate the total cy tochrome P450 (CYP 450) 
contribution to PF -06865571 metabolism was >96% and CYP3A 
isthe predominant isoform 
responsible for the metabolism of PF -06865571.  Modeling suggests a moderate risk of 
clinical drug -drug interac tions (DDI s) with PF -06865571 as a victim upon co -administration 
with CYP3A4 inhibitors or inducers.
Assessment of the DDI potential for PF -06865571 on selected CYP and UDP 
glucuronosy ltransferase ( UGT )enzymes and drug transporters isbased on the predict ed 
mean stead y-state unbound C maxof 555 ng/mL  (~1.36 M) corresponding to the highest dose 
of PF -06865571administered inthecurrent study  (300 mg Q12H)).  PF -06865571 mediated 
DDIs resulting from inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2D6, and CYP3A4/5
are not expected; however, PF
-06865571 does have the potential to inhibit CYP2C9 and 
CYP2C19 at clinically  relevant concentrations.  It is unlikely  PF-06865571 will inhibit UDP 
UGT , 1A4, 1A6, 2B7, and 2B15 enzy mes at clinically  relevant concentrations; however, 
PF-06865571 does have the potential to inhibit UGT1A1 and UGT1A9.  PF -06865571 
demonstrated induction of CYP3A4 and CYP2B6 activity  (mRNA and enzy matic) in human 
hepatocy tes.  At the anticipated highest dose of PF -06865571 in currently  planned clini cal 
trials (300 mg twice daily  [BID]), modeling suggests a moderate change in the exposure of 
CYP3A4 substrates primarily  due to intestinal CYP induction.  I n vitro evaluations indicate 
that PF -06865571 has a low potential to inhibit organic anion transpor ter (OAT)1, OAT3, 
multidrug and toxin extrusion protein (MATE)2K, organic cation transporter (OCT)1, 
organic anion transporting poly peptide (OATP)1B1, and OATP1B3 at clinically  relevant 
concentrations.  However, PF -06865571 does have the potential to inhibit P -gp, breast cancer 
resistance protein (BCRP), MATE1, and OCT2 at clinically  relevant concentrations. 
1.2.3. Summary of Toxicology Studies
PF-06865571 was evaluated in vitro and in vivo in genetic toxicity  studies and safet y 
pharmacolog y studies, in vivo in o ral repeat -dose rat and monkey  toxicit y studies up to 
6weeks duration, and in an in vitro phototoxicity  assessment.  PF -06865571 was not 
mutagenic or clastogenic in in vitr o studies and was negative in in vivo rat micronucleus 
studies.  No significant fin dings were noted in safety  pharmacology  in vitro or in vivo in 
neuropulmonary  and cardiovascular studies in rats and monkey s, respectively .  No adverse 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 14toxicity and no target organs or systems were identified in Wistar Han rats or cynomolgus 
monkeys following single or repeat doses (up to 6 weeks) of PF-06865571 via oral gavage administration at doses up to 1000 (500 BID) mg/kg/day.  These were maximum feasible doses based on dose volume and formulation limitations.  PF-06865571 did not demonstrate phototoxic potential in the neutral red uptake phototoxicity assay in BALB/c 3T3 mousefibroblasts. 
The no observed adverse effect levels (NOAELs) in the 6-week studies were the highest dose 
levels tested, 1000 (500 BID) mg/kg/day with associated unbound maximum observed concentration (C
max) and area under the curve (AUC 24) of 2450/7880 ng/mL and 
25300/103000 ng·h/mL (males/females), respectively, in rats, and 4790 ng/mL and 56900 ng·h/mL
, respectively, in monkeys.  After correction for species differences in protein 
binding, the stopping criteria in humans are set to a C maxof 6940 ng/mL and AUC 24of 
71670 ng·hr/mL (ie, NOAEL exposures observed in rats). 
Additional information for this compound may be found in the single reference safety 
document (SRSD), which for this study is the investigator’s brochure (IB) for PF-06865571. 
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 15CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 161.3. Study Rationale 
The current study is the first to evaluate the effect of PF-06865571 (compared to placebo) on 
liver fat, as assessed via magnetic resonance imaging proton density fat fraction (MRI-PDFF),   The investigational product (IP) will be administered orally for 2 weeks.  
1.3.1. Study Design Rationale 
Along with an assessment of the effect of PF-06865571 on liver fat, this study is designed to 
assess the safety and tolerability of 2 different oral dosing regimens of PF-06865571compared to placebo.  To address the potential effect of PF-06865571 on liver fat, the 
eligible population for study enrollment is subjects with NAFLD, with liver fat ≥6%, as 
assessed by MRI-PDFF at Screen 3.  Subjects who meet all eligibility criteria for the study 
during Screen 1 (including liver fat approximation by FibroScan
®) will then undergo an 
additional liver fat approximation by FibroScan®at Screen 2.  These assessments will provide
an initial estimate of liver fat prior to MRI-PDFF.  FibroScan®is an ultrasound based 
technique that estimates liver fat through calculation of the controlled attenuation parameter 
(CAP™), measured in decibels per meter (dB/m).   
 
 
 CCI
CCI
C
CI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 17Subjects who meet all eligibility criteria for the study during Screen 1 and Screen 
2 (including liver fat approximation by FibroScan®) will then undergo liver fat assessment by 
MRI-PDFF at Screen 3.  The MRI-PDFF technique is an established method that enables 
quantification of fat content in the liver.  Imaging data are acquired with this method in a manner that accounts for confounding factors that can otherwise result in inaccurate measures of liver fat, while also providing whole-liver coverage such that fat content can be assessed across each of the 9 Couinaud liver segments.  This noninvasive methodology has been found to be more sensitive to change in liver fat content than histologically-determined steatosis grade,
14and has been utilized in previous trials of potential NASH therapeutics.15,16
Prior to the assessment of liver fat ( MRI-PDFF), subjects will be 
required to fast (water permitted) for ≥4 hours given the ability of food to impact the imaging 
results (≥8 hours prior to Days -2 and 15 due to lipid sample collection).  Baseline (Day -2) 
assessments for MRI-PDFF should be at approximately the same clock time 
(ie, within a practical window ( ±2 hours) relative to the clock time of the Screening visit).  
All post-dose assessments MRI-PDFF should occur within a 
practical window ( ±2 hours) relative to clock time of each baseline assessment.
Total duration of dosing PF-06865571/placebo in this study is proposed as 2 weeks, as 
supported by completed nonclinical toxicity studies in rats and monkeys.  This duration is also expected to permit sufficient assessment of the primary pharmacology of PF-06865571and its effect on liver fat. Given the current study is the first to administer repeated doses of PF-06865571 to subjects with NAFLD, a baseline day (Day -1) will permit assessment of safety (including triplicate ECGs) and tolerability, ie, change from baseline (CFB, within subject) and placebo-adjusted comparison of dose-response (between subject), as appropriate. 
This study is also designed to assess the effect of PF-06865571 on other PD markers that are 
intended to provide insight into associated metabolic pathways.  
 
 
 
The serial collection of blood samples to permit assessment of PD effect in this study will 
assist in understanding the optimal dosing regimen to potentially characterize the dose (or exposure) response, as well as to build PK/PD understanding. 
PF-06865571 is not anticipated to have a significant effect on body weight, however, to 
contain the influence of inpatient stay on liver fat, subjects will have their body weight assessed on serial days and their daily caloric intake adjusted to minimize change (both increase and decrease) in body weight while inpatient – refer to Section 7.1.4.CCI
CCICCI
CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 18 
 
Creatinine is actively secreted by OCT2/MATE in kidney.  In the setting of OCT2/MATE 
inhibition, serum creatinine levels have been reported to increase slightly.17  In accordance 
with reported literature on OCT2/MATE inhibition, minor increases in serum creatinine have been observed in C2541002 with very limited/no change in cystatin. In order to better assess renal function in the setting of possible PF-06865571-induced OCT2/MATE inhibition resulting in spurious serum creatinine increases, serum cystatin C will be assessed as part ofthe standard safety labs, in addition to serum creatinine, in order to accurately interpret potential changes in glomerular filtration rate (GFR).
18
1.3.1.1. Study Population
This study will enroll overweight and obese male and female subjects who may be treated for 
co-existing conditions, such as diet-controlled type 2 diabetes mellitus (T2DM), hyperlipidemia or hypertension, but who are otherwise clinically stable.  Female subjects will be confirmed to be categorized as non-childbearing potential since at the present time embryo-fetal developmental toxicology studies with PF-06865571 have not been conducted.  In male subjects, appropriate measures to minimize potential transfer of PF-06865571 via semen to a partner are expected to be followed - refer to Section 4.4.4 .
Subjects with a higher body mass index (BMI) of ≥28 kg/m
2will be enrolled to target a 
similar BMI range as patients with NAFLD and NASH.  Subjects with T2DM will be 
permitted in this study, as long as their glycosylated hemoglobin (HbA1c) is ≤7% and their 
T2DM is diet-controlled (ie, they do not require oral or injectable medication treatment for T2DM), as there is a potential for PF-06865571 to (1) mildly increase plasma glucose and insulin levels, and (2) raise levels of metformin, a common medication in T2DM, due to OCT2/MATE inhibition.  Subjects who use tobacco/nicotine-containing products may also be eligible (see Section 4.4 ).  
The eligible population is defined as having liver fat ≥6% as measured by MRI-PDFF at 
Screen 3.  Alt hough NAFLD is a c ondition marked by excessive ( ≥5%) fat accumulation in 
the liver, this study will enroll subjects with liver fat values ≥6% at screening to allow for 
potential measurement variability and help ensure baseline liver fat values are likely ≥5%.  
As it is unknown whether subjects with lower versus higher baseline liver fat values may 
respond differently to therapy, subjects will be stratified at randomization (Day 1) based on 
MRI-PDFF (Screen 3) liver fat ranges of ≥6% to <10%; and ≥10% as a means of providing 
approximate equal balance of liver fat content between the dosing cohorts.  A second-tier stratification will also be applied at randomization (Day 1) based on the presence or absence 
of T2DM (refer to Section 4.3) for additional details.CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 191.3.2. Dose Rationale
 
 
  The dose and dosing regimen required to maximize the PD effects of 
PF-06865571 are not yet established.   
 In order to fully explore the 
effect of DGAT2 inhibition on liver fat, PF-06865571 doses of 50 mg and 300 mg will be administered BID in this study.   
  These total 
daily doses have been well tolerated with an acceptable safety profile in the ongoing multiple 
ascending dose study (C2541002).CCI
CCI
CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 20Table 5. Predicted Steady-State PF-06865571 Exposures with 
Administration of Multiple Doses of PF-06865571 Under Fed Conditions  
Total Daily Dosea
(mg)Regimen Predicted
Cmax
(ng/mL)Predicted
AUC 24
(ng•h/mL)
100 mg 50 mg Q12H 430 2198
600 mg 300 mg Q12H 2174 13238
Abbreviations: Q12H = every 12 hours.
a. Predicted C maxand AUC 24were derived using a preliminary model based on available PK data from 
Studies C2541001 and C2541002.
2. STUDY OBJECTIVES AND ENDPOINTS
Primary Objective: Primary Endpoint: 
•To evaluate the effect of multiple oral doses of PF-
06865571 on whole liver fat, following 14 days of 
administration to subjects with NAFLD.• Relative change from baseline in whole liver fat at 
Day 15, as assessed by MRI-PDFF.
Secondary Objectives: Secondary Endpoints: 
• To evaluate the safety and tolerability of multiple oral 
doses of PF-06865571, administered for 14 days to
subjects with NAFLD.• Assessment of AEs, clinical laboratory tests, vital 
signs and 12-lead ECGs.
• To characterize the plasma exposure of multiple oral 
doses of PF-06865571, administered for 14 days tosubjects with NAFLD.• PF-06865571 C
max, AUC tau, Tmax, Cmin, CL/F, and 
PTR on Day 14, as permitted by the data.
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 213. STUDY DESIGN
3.1. Study Overview
This will be a randomized, double-blind (sponsor-open), stratified, placebo-controlled, 3-arm 
(placebo, plus 2 active doses of PF-06865571), parallel-group study (refer to Figure 1).
Figure 1. Design of Study C2541005
Day -2^
Admission to CRUDay -1
MRI-PDFFInpatient stay at Phase 1 Unit Day -2 to Day 16 
With supervised transportation to MRI Imaging Center on Day 15
Screen 1
Screen 2MRI - PDFF
Follow-up via telephone contact
28-35 days post Day 14Day 1Follow-up Visit
7-10 days post Day 14
Day 15^
MRI-PDFFDay 14
^AllMRI -PDFF images to be read by s ponsor - identified c entral im aging vendo r Days 2 - 13Dosing with double -blind IP x 14 days
PF-06865571 o rmatching placebo 
Day 16
D/C from CRU42days
Screen 3^CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 22A total of approximate ly 45 subjects ( 15 per arm) will be randomized at approximately  4 to 
6sites to ensure a minimum of 42 subjects complete the study (assuming an approximate 
5%
premature withdrawal rate).  Subjects may  be replaced at the discretion of the principal 
investig
ator (PI) and Sponsor .  Subjects will be randomized to receive PF-06865571 
(
2dosing regimens) or matching placebo (1 dosing regimen) in a 1:1:1 ratio.
For a given subject, the total study  duration from Screen 1 to the follow -up phone call will be 
up to approximately  13weeks.  Scr een 1 will occur within 42 days prior to the first dose of 
blinded IP(PF-06865571 or 
matching placebo) .  Eligible subjects who meet the entry  criteria 
will progress to admission on the morning of Day  -2, prior to lunch, for an 18 -day (17-night) 
inpatient stay .  While inpatient, subjects will receive blinded IPfor 14 consecutive day s and 
remain inpatient for approximately  an additional 48 hours post AM dose on Day 14.  
Following discharge on Day  16, subjects will return for an on -site follow -up visit 7 to 
10days following the last dose of blinded IP, and a follow -up phone call 
(or visit, if 
necessary  per the PI) 28 to 35 days following the last dose of blinded IP.
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study  is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol
.
Subject eligibility  should be reviewed and documented by  an appropriate member of the 
investigator’s study team before subjects are included in the study . 
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the 
study :
1.Male subjects or female subjects of non- childbearing potential between the ages of 
18and 65years, inclusive , at Screen 1.
Female subjects of nonchildbearin g potential must meet at least 1 of the following 
criteria:
a.Achieved postmenopausal status, defined as follows : cessation of regular menses for 
at least 12 consecutive months with no alternative pathological or phy siological 
cause; status should be confirm ed with a serum follicle -stimulating hormone (FSH)
level confirming the postmenopausal state;  
b.Have undergone a documented hy sterectom y and/or bilateral oophorectomy ;
c.Have medically  confirmed ovarian failure .
All other female subjects (including female subject s with tubal ligations )areconsidered 
to be of childbearing potential.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 232. At Screen 1 , total body  weight of > 50kg (110 lbs) and a BMI 28kg/m2;
3. At both Screen 1 and Screen 2, a CAPTM260dB/m via FibroScanassessment .  Note: 
if the CAPTMvalue is in the range of 240 -259 dB/m, the FibroScanassessment may  be 
repeated on a different day  following a t least a 4-hour fast; thus 2 assessments (at least 
1of Screen 1 and repeat Screen 1, plus at least 1 of Screen 2 and repeat Screen 2) are 
required to be met above threshold before progressing to Screen 3;
4. At Screen 3, liver fat 6% measured b yMRI -PDFF acquisition protocol at the 
Sponsor -qualified Imaging facility , confirmed via a single repeat, if deemed necessary  by 
the Sponsor -identified central imaging vendor (refer toSection 7.5.1);
5.Evidence of a personally  signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the study ;
6.Subjects who are willing and able to compl y with all scheduled visits, clinical research 
unit ( CRU )confinement, treatment plan, laboratory  tests, and other study  procedures.
4.2.
Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1.Subjects currentl y experiencing an y clinicall y significant or unstable medical condition 
that might limit their ability  to complete the stud y, to comply  with the requirements of the 
protocol, or interfere with the interpreta tion of study  results which, in the judgment of the 
investigator, would make the subject inappropriate for entry  into this study , including: 
dermatologic disease, hematological disease, pulmonary  disease, hepatic disease, 
gastrointestinal disease, genitour inary  disease, endocrine disease, neurological disease 
and psy chiatric disease;
2.Subjects with any of the following clinical laboratory  abnormalities at Screen 1,as 
assessed b y sponsor -identified central laboratory  and confirmed b y a single repeat, if 
deem ed necessary :
Fasting 
TG>400 mg/dL ;
Fasting direct L DL-C >190 mg/dL ;
Aspartate aminotransferase ( AST ), alanine aminotransferase ( ALT ), or gamma 
glutamy l transferase (GGT) >2.0 x upper limit of normal (ULN);
HbA1 c >7.0 %;
Total bilirubin > 1.5x ULN with a direct bilirubin ULN;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 24NOTE: Subjects with a history  of Gilbert sy ndrome would be eligible for this 
study  provided direct bilirubin level is ULN plus ALT met criteria for 
applicable 1sttier stratification plus alkaline phosphatase, hemoglobin, and
reticul ocyte count are ULN.
Albumin < lower limit of normal ( LLN) ;
International normalized ratio (INR) 1.3.
3.A positive urine drug test for illicit drugs at Screen 1.  
NOTE: Subjects who have been medically  prescribed opiates/opioids or 
benzodiazepines and re port the use of these drugs to the investigator at Screen 1 may 
be allowed to partici pate if approved by  the sponsor.
4.History  of regular alcohol consumption exceeding 14 drinks/week for female subject s or 
21drinks/week for male subject s (1drink = 5ounce s [150 mL] of wine or 12 ounces 
[360 mL]of beer or 1.5 ounces [45mL]of hard liquor) within the previous 6 months
from Screen 1;
5.At Screen 1, supine sy stolic blood pressure ( BP)160mmHg and/or diastolic BP 
100mmH g after 5 minutes of rest;  
If neede d, the BP may be repeated 2 more times and the average of the 3 BP values 
willbe used to dete rmine the subject’s eligibility .
6.At Screen 1, triplicate supine 12- lead ECG (average) demonstrating a QTcF interval 
>450 msec or a QRS interval >120 msec ;  
If QT cFexceeds 450msec , or QRS exceeds 120 msec , the ECG should be repeated 
2more times and the average of the 3QTcFor QRS values should be used to 
determine the subject’s eligibility .
7.At Screen 1, subjects with an estimated GFR <60mL/min/1.73m2as calcul ated b y the 
modification of diet in renal disease equation (MDRD) ,andconfirmed via a sin gle 
repeat, if deemed necessary .
8. Evidence or diagnosis of other forms of chronic liver disease ,including but not limited to 
the entities listed below; evidence may  include laboratory tests, as assessed by  the 
Sponsor -identified central laboratory , with a single repeat at Screen 1 permitted to assess 
eligibility , if needed:
Hepatitis B virus (HBV), defined b y presence of hepatitis B surface antigen 
(HepBsAg) and hepati tis B core antibod y (HepBcAb) ;
Hepatitis C virus (HCV), defined b y presence of hepatitis C antibody (HCVAb), and
HCV RNA (when reflexed based on a positive result for HCVAb);

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 25Human Immunodeficiency  Virus (HIV) infection, defined as presence of HIV 
antibody ;
Known diagnosis of primary  biliary  cirrhosis, primary  sclerosing cholangitis, 
autoimmune hepatitis, or overlap s yndrome ;
History  of esophageal varices, ascites, or hepatic encephalopathy ;
Alcoholic liver disease;
Wilson's disease, defined as ceruloplasmi n level <LLN;
Known diagnosis of hemochromatosis;
α-1-antitry psin (A1AT) deficiency , defined as A1AT level <LLN; 
Prior known drug
-induced liver injury ;
Known or suspected hepatocellular carcinoma or other liver cancer;
History  of liver transplant, current placement on a liver transplant list, or current 
model of end- stage liver disease (MELD) score >12;
Histological presence of cirrhosis on prior biops y.
9.Subjects with anyof the following medical conditions: 
Any condition possibly  affecting drug absorption (eg, prior bariatric surgery , 
gastrectom y, ileal resection);
Diagnosis of ty pe 1 diabetes mellitus; 
Diagnosis of T2DM requiring pharmaceutical treatment(s);
NOTE: Subject s with diet- controlled T2DM who have an HbA1c ≤7.0 are 
permitted in this study .
Recent (ie, within the previous 6 months) history  of congestive heart failure 
(New York Heart Association, NYHA ,class III or IV) or unstable angina;
A history  of m yocardial infarction, stroke ,ortransient ischemic attack, in the 
previous 6 months of Screen 1;
Any malignancy  not considered cured (except basal cell carcinoma and squamous cell 
carcinoma of the skin); a subject is considered cured if there has been no evidence of 
cancer recurrence in the previous 5 years;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 26Active placement of medical devices in/on thoracic or abdominal cavities such as 
pacemakers, defibrillators.
10.Subjects with any anatomical or pathological abnormality  that would either preclude or 
tend to confound the analysis of stud y data, including an y clinically  significant abnormal 
findings on MRI  obtained at Screen 3, by  the Sponsor -identified central imaging vendor, 
or subjects meeting criteria for contraindication for MRI , including the following:
History  of severe claustrophobia impacting ability to perform MRI during the study  
despite 
mild sedation/treatment with an anxioly tic;
Subjects with metal implants, devices, paramagnetic objects contained within the
body ,and excessive ormetal -containing tattoos;
Subjects unable to lie still within the e nvironment of the MRI  scanner ormaintain a 
breath hold for the required period to acquire images despite mild sedation/treatment 
with an anxioly tic;
Subjects with abdominal girth greater than the bore sizeof the site’s MRI  system.
11.Subjects taking any  prohibited concomitant medication(s) orthose unwilling/unable to 
switch to permitted conc omitant medication(s) [refer to Section 5.8];
12.Weight loss of 
5% within 1 month prior to Screen 1;
13.Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing 
potential; fertile male subjects who are unwilling or unable to use highl y effective 
method (s) of contraception as outlined in this protocol (Section 4.4.4) for the duration of 
the study  and for at least 28days after the last dose of IP;
14.Blood donation (excluding plasma donations) of approximately  1pint (500 mL)or more
within 56days prior to Screen 1 or during 
the study  until the on- site follow -up visit ;  
15.History  of sensitivity  to heparin or heparin -induced thrombocy topenia only if heparin is 
used to flush intravenous catheters ;  
16. Treatment with an investigational drug within 30 days (or as determined by  the lo cal 
requirement) or 5 half-lives preceding the first dose of IP(whichever is longer);  
17.Subjects with known prior participation in a trial involving PF -06865571 (ie, received at 
least 1 dose of IP);
18.Unwilling or unable to comply  with the criteria in Section 4.4 of this protocol ;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 2719. Investigat orsite staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the investigator , orsubjects 
who are Pfizer emplo yees, including their family  members, directl y involved in the 
conduct of the study ;
20. At Screen 1, other acute or chronic medical or ps ychiatric condition including recent 
(within the past y ear) or activ e suicidal ideation or behavior or laboratory  abnormality  
that may  increase the risk associated with study  participation or IPadministration or may  
interfere with the interpretation of study
 results and, in the judgment of the investigator, 
would make the subject inappropriate f or entry  into this study .
4.3. Randomization Criteria 
On Day  1, interactive response technolog y (IRT) will be used to assign each eligible subject 
a randomization number, with this number recorded on the electronic Case Report Form 
(CRF) .  A computer -generated randomization code using the method of random permuted 
blocks will be utilized to randomize 
subjects in 1:1 :1ratio (1of 2active dosing regimens of 
PF-06865571 or placebo) prior to the first dose of IP,provided subjects satisfy  allof the 
eligibility  criteria outlined in Section 4.1 andSection 4.4.2.
An attempt will be made to equally  balance the number o f subjects assigned to
receive PF -
06865571 versus placebo within each stratum by  utilizing a 2 -tiered 
stratification scheme as follows.  Subjects will be stratified at randomization (Day 1) 
first by  the MRI -PDFF liver fat measurement determined by  the Sponsor -identified 
central 
imaging vendor of images obtained during Screen 3:
Screening liver fat 6% and<10%;
Screening liver fat 10%.
Subjects will then be stratified by  the presence or absence of T2DM.
4.4.Lifestyle Requirements
After confirmation of eligibility  at Screen 3, subje cts will be instructed to maintain the 
guidelines described below for the duration of participation in the study .  The following 
guidelines are provided .
4.4.1.
Meals and Dietary Restrictions
  4-hour fast (except water) prior to:
Liver fat assessment at Screen 3using MRI -PDFF acquisition.
  8-hour overnight fast(except water) prior to:
Any blood collection for lipid s;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 28Liver fat assessment on Day  -2and Day  15 via FibroScanor MRI -PDFF .
As dosing occurs with meal/snack , restriction regarding water intake prior to or after 
dosing is not expected.
Noncaffeinated drinks (except grapefruit or grapefruit -related citrus fruit juices -see 
below) may  be consumed with meals and the evening snack.
Breakfast will be provided approximatel y 30 minutes prior to AM dosing at 0 H and is 
expected to be completed approximatel y 10 minutes prior to AM dosing.
Lunch will be provided approximately  4hours after dosing at 0H.
Dinner will be provided approximatel y 10 hours after dosing at 0H.
A snack consisting of at least 400 kcals will be provided at approximate ly 12 hours 
after the morning dose. 
The snack will be provided approximatel y 20 minutes prior to dosing.
Subjects will not be allowed to eat or drink grapefruit or grapefruit -related citrus 
fruits (eg, Seville oranges, pomelos) from 7 days prior to the first dose of IPuntil 
collection of the final PKblood sample .
While confined, the total daily nutritional composition should be approximately  
55% carboh ydrate, 3 0 % fat, and 15% protein.  
The daily  caloric intake per subject sho uld notexceed approxim ately  3,200 kcal.
The nutritional macronutrient composition consumed by  each subject should be 
maintained, as much as practicall y possible, during the inpatient stay – though 
adjustment may  be necessary  based on serial assessment of body  weight –refer to 
Schedule of Activities –Table 
1and Table 2as well as Section 7.1.4.
In a given subject, 
meals and snacks provided on Day s -2, -1, 1, 14, and 15 must be 
identical and subjects encouraged to complete consumption of each meal/snack, 
whenever possible;
Meals and snacks offered on other day s may  vary  
–both for ty pes of foods as well as 
macronutrie nt content.
4.4.2. Alcohol, Caffeine ,and Tobacco
Subjects will abstain from alcohol for 24 hours prior to admission to the CRU and 
continue abstaining from alcohol until collection of the final PK sample.  Subjects 
may undergo an alcohol breath test or blood alc ohol test at the discretion of the 
investigator .

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 29Subjects will abstain from caffeine -containing products for 2 hours prior to ECG and 
vital sig nmeasurements .  
Subjects will abstain from the use of tobacco -or nicotine -
containing products for 
24hours pri or to dosing and during confinement in the CRU .  
4.4.3. Activity
Subjects will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests.  Walki ng at a normal pace will be permitted.
4.4.4. Contraception
All fertile 
male subjects who are, in the opinion of the investigator, sexually  active and at risk 
for pregnancy  with their partner(s) must agree to use a highly  effective method of 
contraception consist ently  and correctl y for the duration of the active treatment period and 
for at least 28 daysafter the last dose of IP.  The investigator or his or her designee, in 
consultation with the subject, will confirm that the subject has selected anappropriate 
method of contraception for the individual subject and his partner (s)from the permitted list 
of contraception methods (see below) 
and will confirm that the subject has been instructed in 
its consistent and correct use.  At time points indicated in the Schedule of A ctivities, the 
investigator or designee will inform the subject of the need to use highl y effective 
contraception consistently and correctl y and document 
the conversation and the subject’s 
affirmation in the subject’s chart (subjects need to affirm their consistent and correct use of at 
least 1 of the selected methods of contraception) .  In addition, the investigator or designee 
will instruct the subject to call immediately  if the selected contraception method is 
discontinue d or if pregnancy  is known or suspected in subject’s partner . 
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal ),provided the male 
subject’s female partner plans to remain on the same treatment thro ughout the entire 
study  and has been using that hormonal contraceptive for an adequate period of time 
to ensure effectiveness.
2.Correctly placed copper -containing intrauterine device (IUD). 
3.Male condom or female condom used WI TH a separate spermicide product (ie, foam, 
gel, film, cream, or suppository ).  For countries where spermicide is not available or 
condom plus spermicide is not accepted as highly  effective contraception, this option 
is not appropriate.
4. Male sterilization with absence of sperm in the postvasectomy  ejaculate.
5.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 30NOTE: Sexual abstinence, defined as completel y and persist ently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
All sexually  activ e male subjects must agree to prevent potential transfer to and exposure of 
partner(s) to drug through ejaculate b y using a condom consistently  and correctl y, beginning 
with the first dose of IP and continuing for at least 28 days after the last dose of IP.
4.5.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study is documented in the study  contact list located in the supporting study  documentation .
To facilitate access to appro priatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and IPidentifiers, subject study  number s, contact information for the 
invest igatorsite,and contact details for a contact center in the event that the investigator site 
staff cannot be reached to provide advice on a medical question or problem originating from 
another healthcare professional not involved in the subject’ s particip ation in the study . The 
contact number can also be used by  investigator staff if they  are seeking advice on medical 
questions or problems; however ,it should be used only in the event that the established 
communication pathways between the investigator site and the study
 team are not available. 
It is therefore intended to augment, but not replace, the established communication pathway s 
between the investigat orsite and the study  team for advice on medical questions or problems 
that may  arise during the st udy. For sites other than a Pfizer CRU, t he contact number is not 
intended for use b y the subject directl y,and if a subject calls that number ,he or she will be 
directed back to the investigator site.
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmoni sation ( ICH)
guidelines, IPis defined as a pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference /comparator in a clinical trial, including a product with a 
marketing authorization when used or assembled (formulated or packaged) in a way  different 
from the approved form, or when used for an unapproved indication, or when used to gain 
further information about an approved use (ICH E6 1.33).
For this study , the IPsare PF -06865571 and matching placebo and will be administered as 
oral tablets.
5.1.Allocation to Treatment
TheIRT system will be used to sequentially  assign a unique 8 -digit subject identification 
number to each subject who has signed the informed consent document ( ICD).  This 
identify ing number will be retained throughout the duration of study participation.  

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 31Allocation of subjects to treatment groups will proceed through the use of an I RT system.  
The site personnel (stud y coordinator or specified designee) will be required t o enter or select 
information including but not limited to the user’s identification (ID) and password, the
protocol number, and the subject number. The site personnel will then be provided with a 
randomization number .  The I RT sy stem will provide a confi rmation report containing the 
subject number andrandomization number .The confirmation report must be stored in the 
site’s files.
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system. 
A computer generated randomization schedule will be used to assign approximately  
45
subjects in a randomization ratio of 1:1:1 of the 3 treatment groups described in Table 5.  
The randomization number will be recorded in the CRF. In accordance with the 
randomization number, 
the subject will receive the study  regimen assigned to the 
corresponding randomization number.
Table 5. Study Treatment Regimens and Dispensing Schedule
Treatm ent 
GroupTreatm ent 
Regim enMorning Evening
A Placebo Q12H 3 x 
Placebo tablet s3 x 
Placebo tablet s
B 50mg 
PF-06865571  
Q12H1 x 50 mg tablet
PLUS
2 x Placebo tablet s1 x 50 mg tablet
PLUS
2 x Placebo tablet s
C 300 mg
PF-06865571   
Q12H3 x
100 mg tablets3 x
100 mg tablets
In order to maintain the double -blind design 50mg, 100mg, and matching placebo 
tablets will be supplied in the same size and shape ;
All dosing regimens (A -C) will consist of 3 tablets (representing PF-06865571 or 
matching placebo) administered Q12H .
5.2.Breaking the Blind 
The s tudy will be subject -and investigator -blinded.
At the initiation of the study , the investigator site will be instructed on the method for 
breaking the blind.  The method will be an electronic process.  Blinding codes should be 
broken only in exceptional c ircumstances when knowledge of the actual treatment code is 
absolutely  essential for further management of the subject.  Investigators are encouraged to 
discuss with a member of the study  team if they  believe that unblinding is necessary .  When 
the blindin g code is broken, the reason must be fully  documented and entered on the CRF .

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 32This is a ninvestigator -and subject -blind ( Sponsor open) placebo -controlled study .  Blood 
specimens will be obtained from all subjects for pharmacokinetic anal ysis to maintain t he 
study  blind at th e investigator site.  The investigator site(s) staff [ with the exception of the 
site pharmacist(s) and pharmacy  assistant(s)], and blinded study  monitor(s), will be blinded 
to investigational product (PF- 06865571 or placebo) .  Other spe cified Pfizer personnel , 
including the separate unblinded monitor(s) assigned , will be unblinded to subject 
treatments.  The blinded study monitor will remain blinded to treatment until all 
monitoring for the study has been completed .  
Specimens from subj ects randomized to placebo will not be routinely  analy zed.  To minimize 
the potential for bias, treatment randomization information will be kept confidential by  Pfizer 
unblinded personnel and will not be released to the blinded investigator or blinded 
investigator site personnel until the study  database has been locked or the investigator 
requests unblinding for safet y reasons .
5.3.Subject Compliance
IPwill be administered under the supervision of investigator site personnel.  The oral cavity  
of each subject w ill be examined following dosing to ensure the IPwas taken.
5.4.Investigational Product Supplies
5.4.1. Dosage Form and Packaging
IPwill be supplied by  the Sponsor as PF-06865571 50 mg and 100 mg, and matching 
placebo tablets for oral administration .  The tablets will be supplied as white to off -white 
tablets packaged in bottles and labeled according to local regulatory  requirements. 
5.4.2. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the IPready for administration or dispensing to the subject/caregiver b y qualified staff.  
Dispensing is defined as the provision of IP, concomitant treatments, and accompany ing 
information by  qualified staff member(s) to a healthcare provider, subject, or caregiv er in 
accordance with this protocol.  L ocal health authority  regulations or 
investigator site 
guidelines may  use alternative terms for these activities.
Tablets will be supplied at the CRU in the individual dosing containers b y 2operators , 1 of 
whom is a n appropriatel y qualified and experienced member of the stud y staff ( eg, phy sician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist) .
Thetablets will be provided in dose containers and labeled in accordance with Pfizer
regulations and the clinical site’s labeling requirements. 
5.5.Administration
Administration of blinded IPwill occur under the conditions described in Section 4.4.1.  
Subjects will r eceive the 
first dose of IPat approximately  08:00 hours local time (plus or 
minus 2 hours).  The second dose will be administered approximatel y 12 hours later.  
Investigator site personnel will administer IPwith ambient temperature water to a total 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 33volum e of approximatel y 240 mL.  Subjects will swallow the IPwhole, and will not 
manipulate or chew the IPprior to swallowing. 
5.6.Investigational Product Storage 
The investigator or an approved representative, eg, pharmacist, will ensure that all IPsare 
store
d in a secured area with controlled access under required storage conditions and in 
accordance with applicable regulatory  requirements.
IPsshould be stored in their original container sand in accordance with the labels. 
Any storage conditions stated in the SRSD (ie, IBfor PF -06865571) will be superseded b y 
thestorage conditions stated on the product label. 
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all si te storage locations (as 
applicable, including frozen, refrigerated ,and/or room -temperature products).  This should 
be captured from the time of IPreceipt throughout the study .  Even for 
continuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capabilit y to store or view the min imum/maximum
temperature for all non- working day s upon return to normal operations.  The operation of the 
temperature -monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they aremaintained in working order. 
Any excursions from the product -label storage conditions should be reported to Pfizer upon 
discovery .  The site should actively  pursue options for returning the product to thestorage 
conditions described in the labeling , as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer . 
Once an excursion is identified, the IPmust be quarantined and not used until Pfizer provides 
permission t o use the IP.  It will not be considered a protocol deviation if Pfizer approves the 
use of the investigational product after the temperature excursion. Use of the IPprior to 
Pfizer 
approval will be considered a protocol deviation. Specific details regarding 
information the site should report for each excursion will be provided to the site. 
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefl y out of thetemperature range described in the la beling are not 
considered excursions.
5.7. Investigational Product Accountability
The investigat or site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the IPsupplies.  All IPs will be accounted for using a drug acc ountability  
form/record. 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 345.7.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance on the destruction of unused IP(eg, at the 
site).  If destruction is authorized to take place at the investigator site, the investiga tor must 
ensure that the materials are destro yed in compliance with applicable environmental 
regulations, institutional policy , and any  special instructions provided by  Pfizer ,and all 
destruction must be adequately documented.
5.8.Concomitant Treatment s
Subje cts in this study will be allowed to take certain concomitant medications to treat 
coexisting conditions such as hy perlipidemia and hy pertension.  All concomitant treatments
taken during the stud y must be recorded with indication, daily dose, and start and stop dates 
of administration.  Attempts must be made notto alter the doses and regimens of chronic 
background medications after randomization and for the duration of participation in this 
study .  An y changes made to background medications must be capture d in the CRF.  All 
subjects will be questioned about concomitant treatment at each study visit.
Treatments taken within 42days before the first dose of IPon Day  1 will be documented as a 
prior 
treatment .  Treatments taken after the first dose of IPwill be documented as 
concomitant treatment s
.
5.8.1. Anti -Hypertensive Medications
Use of background antihy pertensive agent( s) is permitted .  Doses of antih ypertensive agents 
should be stable for at least 8weeks prior to Screen 1
.  
5.8.2. Lipid -Modifying Medications
Subjec ts are permitted to be on stable doses of the following lipid-modify ing agents, starting 
at 8 weeks prior to Screen 1 and until on-site Follow -upvisit, including (but not limited to) 
the following:
Statins such as atorvastatin, simvastatin, pitavastatin , pravastatin;
Note :rosuvastatin and fluvastatin are notpermitted as detailed below;
Ezeti mibe ;
Bile acid sequestrants such as cholest yramine, colestipol , colesevalam ;
Gemfibrozil and fenofibrate;
Nicotinic aci d/niacin.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 35The use of the following medications or classes of agents is notpermitted within the 
timelines specified:  
•Rosuvastatin or fluvastatin within 4 weeks prior to Screen 1 and until on-site 
Follow-up visit;
•Monoclonal antibodies inhibiting such as alirocumab and evolocumab, 
within 12 weeks prior to Screen 1 or within 5 half-lives of dose administered 
(whichever is longer), and until on-site Follow-up visit.
5.8.3. Other Acceptable Concomitant Medications
Subjects on the following list of medications must be on stable doses (ie, at least 8weeks 
prior to Screen 1) and for the duration of participation in the study through on-site Follow-up visit:
•Inhaled and topical corticosteroids;
•Thyroid replacement therapy;
•Postmenopausal hormone therapy;
•Non-steroidal anti-inflammatory medications (NSAIDs) such as ibuprofen, 
ketoprofen, naproxen, indomethacin, and meloxicam.  Intermittent use of these 
medications is also permitted;
•Intermittent use of acetaminophen/paracetamol at doses ≤1 gram per day;
•Aspirin at doses ≤325 mg per day;
•Antidepressant medications such as tricyclic agents, selective serotonin reuptake 
inhibitors, and serotonin/norepinephrine reuptake inhibitors;
•Certain herbal supplements but only
following consultation with Sponsor;
•Limited use of nonprescription medications that are not believed to affect subject 
safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
5.8.4. Prohibited Concomitant Medications
Subjects must abstain from using allanti-diabetic medications for ≥12 weeks prior to Screen 
1 and until on-site Follow-up visit, including the following:
•Biguanides, such as metformin; 
•Sulfonylureas such as glyburide, acetohexamide, chlorpropamide, tolazamide, 
tolbutamine, glimepiride, glipizide;CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 36Dipeptidy l peptidase-4 (DPP -4i)inhibitors such as sitagliptin, saxagliptin, 
vildagliptin;

-glucosidase inhibit ors such as acarbose and miglitol;
TZDs such as pioglitazone and rosiglitazone; 
Subcutaneously  administered agents for gl ycemic control (eg, insulin, exena tide, 
liraglutide, pramlintide);
Sodium -glucose co- transporter 2 inhibitors such as canagliflozin, dapagliflozin, 
empagliflozin .
Subjects must abstain from using the following medications for 4weeks prior to Screen 1
and until on- site Follow -upvisit:
Chronic use of systemic glucocorticoids such as prednisone, dexamethasone, 
triamcinolone, budesonide, betamethasone
; and immunosuppressants such as 
tacrolimus;
Pharmacological agents with approved indication for weight loss such as orlistat and 
sibutramine; 
Over -the-counter appetite -simulant or appetite- suppressant, as advertised; 
(Medical -grade) marijuana, r egardless of medical indication.
Specific classes of agents given that the current study is the first study  in a patient 
population:
Coumadin- type anticoagulants orother anticoagulants (eg, dabigatran); 
Anticonvulsants;
Antiarrh ythmics , except for beta blockers or calcium channel blockers if used 
for the management of conditions other than arr hythmias .
Medications h istorically  associated with fatt y liver are prohibited if used for 
4 week s ofcontinuous use in the previous 12 months prior to Screen 1 , examples 
include : 
Amiodarone, methotrexate, tetracy clines, tamoxifen, estrogens at doses 
greater than those used for hormone replacement, anabolic steroids, valproi c 
acid, other known hepatotoxins ;
Strong inducers and inhibitors of CYP3A enzy me(seeAppendix 2);

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 37•BCRP and P-gp substrates (eg, rosuvastatin and digoxin);
•Sensitive CYP2C9 substrates (eg, fluvastatin, diclofenac, celecoxib, 
torsemide).
5.9. Rescue Medication
There is no rescue therapy to reverse AEs observed with administration of IP; standard 
medical supportive care should be provided to manage the AEs.
6. STUDY PROCEDURES
A signed and dated ICD will be obtained from each subject at Screen 1 before performing
any protocol-specific procedures.  All requirements and procedures of the trial will be thoroughly reviewed with all subjects.  The results of the clinical laboratory assessments and all screening procedures will be evaluated with respect to inclusion and exclusion criteria to determine the subject’s eligibility.  If a subject does not qualify for the trial, he or she will be considered a screen failure.  Adverse Event (AE) reporting, including Serious Adverse 
Event (SAE) reporting will begin from the time the ICD is signed at Screen 1.
6.1. Proposed Chronology of Procedures
For the study period described below, when multiple procedures are scheduled at the same 
time point(s) relative to dosing, the following chronology of events should be adhered to, where possible .
•12-lead ECG : obtain prior to vital signs assessment, blood samples, and prior to 
dosing (refer to Section 7.1.6 ).
•Vital Signs (BP and pulse rate) : obtain after 12-lead ECG collection but prior to 
obtaining blood samples and prior to dosing (refer to Section 7.1.5 ).
•Fasting blood samples : after assessment of 12-lead ECG and vital signs but prior to 
dosing (refer to Section 7.1.1 ).
•Serial blood samples for plasma PK, insulin, as close 
as practically possible to the scheduled time (refer to Schedule of Activities ).
•If the post-dose blood collection nominal time coincides with the nominal time of 
a meal, these blood samples should be collected just prior to
meal/snack.
•Other pre-dose procedures : should be obtained/performed as close as possible to the 
scheduled time, but may be obtained before or after blood specimen collection.
•Dosing : must occur at the scheduled nominal time (refer to Section 5.5 ) and following 
pre-dose blood sample collection.CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 38•Ifan intravenous catheter is placed for serial blood sample collections, ECGs and 
vital signs (pulse rate, BP) assessments should be either collected prior to the 
insertion of the catheter or sufficient rest period after catheter insertion introduced to minimize impact of catheter placement on these assessments.
6.2. Screening
Refer to the Schedule of Activities Table 1 for the study procedures to be completed at the 
Screening visits.  The 3
screening visits are to be performed sequentially .  
•At Screen 1, subjects will be consented and all screening procedures (except assessment 
of liver fat by MRI-PDFF) undertaken to determine eligibility – refer to Sections 4.1
and4.2;  
•Only after subjects are identified to be otherwise eligible, should they proceed with 
Screen 2 for another FibroScan®assessment as performed at Screen 1;
•Following confirmation of all eligibility at Screen 2, subjects should proceed to the 
Imaging center for the Screen 3 visit to undergo liver fat assessment via MRI-PDFF 
acquisition to assess whether they meet inclusion criterion #4, Section 4.1 .  
Subjects will be screened within 42 days prior to the first dose of the blinded IP to confirm 
that they meet the subject selection criteria for the study.  The investigator (or an appropriate delegate at the investigator site) will obtain informed consent from each subject in accordance with the procedures described in Section 12.3 .  
In rare
cases, subjects may be re-screened; however, this is permitted only when, due to 
logistical constraints , the maximum period between the Screen 1 and Day 1 of 42 days is 
exceeded.  In such cases, all screening procedures must be repeated and the subject assigned a new 8-digit SSID number.  Subjects must be deemed to meet all the eligibility criteria including assessment of liver fat via MRI-PDFF at Screen 3, under the new 8-digit SSID.
To prepare for study participation, subjects will be instructed on the use of Lifestyle 
Requirements ( Section 4.4 ) and Concomitant Treatments ( Section 5.8 ).
6.3. Study Period
Refer to the Schedule of Activities for the study procedures to be completed. 
 
 
If a subject has any clinically significant, study-related abnormalities at the conclusion of a 
scheduled inpatient portion of the study, the Pfizer medical monitor (or designated representative) should be notified and the subject may be asked to remain in the CRU until such abnormalities are deemed not clinically significant, or it is safe for outpatient follow-up.  CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 39If the subject is unable or unwilling to remain in the CRU and/or when outpatient follow -up 
is deemed appropriate, the Pfizer medical monitor (or designated representative) should be so 
notified, and the investigator should make every effort to arrange follow -up evaluations at 
appropriate intervals to document the course of the abnormalities.
6.4.Follow -up 
In this stud y, there are 2follow -ups, as listed below:
1stfollow -up is an on -
site visit where the subjects will return to the CRU between 
7to 10days following the lastdose of IP.
2ndfollow -up is a telephone contact that will occur 28to 35days following the last
dose of IP.  If the PI deems it necessary , this contact may  be a visit.
Refer to the Schedule of Activities for the study  procedures to be completed at each
of the 2 follow -ups.
6.5.Subject Withdrawal
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also 
Section 8.1.3) or behavioral reasons, or the inability of the subject to comply with the 
protocol -required schedu le of study  visits or procedures at a given investigator site.  The 
early termination visit applies only  to subjects who are randomized and then are prematurel y 
withdrawn from the study.
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  The investigator or site staff should attempt to contact the subject twice.  After 
2attempts, CRU staff may send a registered letter.  If no response is received from the 
subject, the subject will be considered lost to follow -up.  All attempts to contact the subject 
and information received during contact attempts must be documented in the subject’s 
medical record.  In an y circumstance, every  effort should be made to document subject 
outcome, if possible.  The investigat or should inquire about the reason for withdrawal
,
request that the subject return for a final visit, if applicable, and follow up with the subject 
regarding an y unresolved AEs.
It may  be appropriate forthe subject to return to the clinic for final safet yassessments to be 
scheduled as earl y as practically feasible following the decision to withdraw from the stud y.  
Subjects should be questioned regarding their reason for withdrawal.  At the 
early-withdrawal visit, every  effort must be made to complete the following a ssessments:
Conduct an inquiry  about any  spontaneousl y reported AEs by asking the subject to 
respond to a non- leading question such as “how do y ou feel?”
Fullphysical examination, if there is a new or open AE or clinicall y significant 
abnormal physical finding from the last visit (refer to Section 7.1.3);

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 40•Supine, single standard 12-lead ECG measurement (refer to Section 7.1.6 );
•Single, supine BP and pulse rate measurements (refer to Section 7.1.5 );
•Blood and urine specimens for clinical laboratory tests (refer to Section 7.1.1 );
•Blood sample for PK analysis for PF-06865571 (refer to Section 7.2 );
•Blood for cystatin C (refer to Section 7.1.2 );
•Blood for insulin (refer to Section 7.3.4 ).
Lack of completion of all or any of the withdrawal/early termination procedures will not be 
viewed as protocol deviations as long as the subject’s safety was preserved.
If the subject withdraws from the study and also withdraws consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be collected.  The sponsor may retain and continue to use any data collected before such withdrawal of consent.
Withdrawal of consent: 
Subjects who request to discontinue receipt of study treatment will remain in the study and 
must continue to be followed for protocol-specified follow-up procedures.  The only exception to this is when a subject specifically withdraws consent for any further contact with him or her or persons previously authorized by the subject to provide this information.  Subjects should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible.  The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt of investigational product or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page.  In the event that vital status (whether the subject is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.
Lost to follow-up:
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status.  This includes follow-up with persons authorized by the subject as noted above.  All attempts should be documented in the subject’s medical records.  If it is determined that the subject has died, the site will use locally permissible methods to obtain the date and cause of death.  If the investigator’s use of a third-party representative to assist in the follow-up CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 41portion of the study  has been included in the subject’s informed consent, then the investigator 
may use a sponsor -retained third- party representative to assist site staff with obtaining the 
subject’s contact information or other public vital status data necessary  to complete the 
follow -up portion of the study .  The site staff and representative will consult publicly  
available sources, such as public health registries and databases, in order to obtain updated 
contact information.   If, after all attempts, the subject remains lost to follow- up, then the 
last-known- alive date as determined by  the investigator should be reported an d documented 
in the subject’s medical records.
7.ASSESSMENTS
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the subject.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
Refer to Section 6.1 for the recommended order of collection when multiple procedures are 
scheduled at the same time point.
7.1.Safety
7.1.1. Laboratory Tests
The following clinical laboratory  tests will be performed at times defined in the Schedule of 
Activities.  Additional laboratory  results may be reported on these samples as a result of the 
method of anal ysis or the ty pe of anal yzer used b y the clinical laboratory; or as derived from 
calculated values.  These additi onal tests would not require additional collection of blood.  
Unscheduled clinical lab oratory  measurements may be obtained at any  time during the study  
to assess an y perceived safet y concerns.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 42Table 6. Clinical Laboratory Tests
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC countMCV
MCH
MCHCPlatelet countWBC countTotal neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN/urea 
CreatininePlasma
glucose (fasting)
Calcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALTTotal bilirubin
Alkaline phosphatase
GGTTotal bile acidsUric acidAlbumin
Total protein
Direct bilirubin
d
Indirect bilirubind
Serum cystatin CpH
Glucose (qual)Protein (qual)Blood (qual)
Ketones
NitritesLeukocyte esteraseUrobilinogenUrine bilirubinMicroscopy
a•FSHb
•Urine drug testc
•Serology: HIV, 
HepBsAg, 
HepBcAb, HCVAb
(and if positive, reflex HCV RNA)
c
•A1ATc
•HbA1cc
•Ceruloplasminc
•PT/INRc
Additional Tests (Needed for Hy’s Law)
•AST, ALT (repeat)
•Total bilirubin (repeat)
•Albumin (repeat)
•Alkaline phosphatase (repeat)
•Direct bilirubin
•Indirect bilirubin
•Creatine kinase
•GGT
•PT/INR
•Total bile acids
•Acetaminophen drug and/or protein adduct levels
a. Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase.
b. At Screening only, in all females. c. At Screening only.d. Direct and indirect bilirubin measured only when total bilirubin is >ULN.For a list of abbreviations, refer to Appendix 1 .
•The minimum requirement for drug screening includes cocaine, tetrahydrocannabinol
(THC), opiates/opioids, benzodiazepines, and amphetamines.
•Subjects may undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for subjects to receive IP. 
•Estimated glomerular filtration rate (eGFR) will be calculated using the modification 
of diet in renal disease (MDRD) equation.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.   
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 43 
  These data will not be included in the clinical study report (CSR).  Samples 
to be used for this purpose will be shipped to either a Pfizer-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.
7.1.2. Serum for Cystatin C
Blood samples (approximately 2.5 mL) to provide a sufficient quantity of serum for analysis 
of cystatin C will be collected into appropriately labeled tubes at pre-specified nominal time points outlined in the Schedule of Activities . GFR will be estimated from the cystatin C 
using the CKD-Epi-Cystatin C equation
18provided below.
•For serum cystatin C (Scys) ≤0.8 mg/L:
eGFR = 133×(Scys/0.8) -0.499×0.996 Age[×0.932 if female]
•For serum cystatin C (Scys) >0.8 mg/L:
eGFR = 133×(Scys/0.8) -1.328×0.996 Age[×0.932 if female]
7.1.3. Physical Examinations
Physical examinations may be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptable according to local regulation.  A full physical examination will include head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems.  The limited or abbreviated physical examination will be focused on general appearance, the respiratory and cardiovascular systems, and subject-reported symptoms.
7.1.4. Body Weight
In this study, assessment of body weight will occur at the nominal time points specified in 
the Schedule of Activities per the following specifications –
•Weight will be recorded using a calibrated scale placed on a stable, flat surface;
•During the inpatient stay
, the same scale will be used with the scale reporting weight in 
kilograms, and accuracy to the nearest 0.1 kg [ie, the device must be able to distinguish a 
difference between 68.4 kg and 68.3 kg];
•Measurement must be undertaken –
•At approximately the same time of the day, in the morning in the fasting state, at each 
nominal time point while inpatient ;
•After the subject has been asked to void (ie, forced void);CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 44Under standard conditions (eg, subjects must wear light clothing with content of their 
pockets emptied orhospital gown and notbe wearing shoes or bulky  layers of 
clothing/jackets);
With subjects remaining still while on the weighing scale.
7.1.4.1. Adjustment of Caloric Intake to Maintain Stable Body Weight
Daily  caloric intake, while inpatient , should be adjusted base d on each serial assessment 
of body  weight after Day 1 –refer to Section 4.4.1 ;
The initial caloric intake/menu assigned to each subject will be based on the Harris 
Benedict formula (sedentar y lifest yle; to be provided to the site prior to study  start) using 
the subject’s body  weight measured at screening;
Caloric intake should be adjusted, on the day s when body  weight is assessed, to ensure 
that the subjects do notgain or lose bod y weight –defined as no more than 1.0 kg 
change in bod y weight on any day post Day 1 compared to the body weight at Screen 
1;
NOTE : on selected days when meals and snacks offered are to be identical (ie, Days -2, 
-1, 1, 14,and 15), while body  weight measurements may  occur on some of these day s, 
adjustment to caloric content on these selected days must notoccur.
7.1.5. Blood Pressure and Pulse Rate
BPand pulse rate will be measured at times specified in theSchedule of Activities section of 
thisprotocol.  Additional collection times, or changes to collection times ,of BPand pulse 
ratewill be permitted, as necessary , to ensure appropriate collection of safety  data.
Supine BPwill be measured with the subject’s arm supported at the level of the heart ,and 
recorded to the nearest mmHg after approximatel y 5minutes of rest .  The same arm 
(preferabl y the dominant arm) will be used throughout the study. Subjects should be 
instructed not to speak during measurements.
The same properl y sized and cali brated BP cuff will be used to measure BPeach time.  The 
use of an automated device for measuring BP and pulse rate isacceptable ;however , when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds.  
7.1.6. Electrocar diogram 
In this stud y, 12 -lead ECGs will be collected at the nominal time points specified in the 
Schedule of Activities per the following specifications:
All scheduled 12- lead ECGs should be performed after the subject has rested quietly  for 
10minutes in a supine position;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 45Triplicate 12 -lead ECGs will be obtained approximately  2to 4minutes apart; the average 
of the triplicate ECG measurements collected prior to the first dose on Day 1will serve as 
each subject’s baseline valu e.
If the average of QTc Fvalues from the triplicate measurements remains above the 
threshold value ( ie, is  45msec from the baseline , or is  500msec), then a single ECG 
must be repeated at least hourly  until QTc Fvalues from 2 successive ECGs fall belo w the 
threshold value that triggered the repeat measurement .
If QTc Fvalues remain 500msec (or 45msec from the baseline) for greater than 
4hours (or sooner ,at the discretion of the investigator) ,or QTc Fintervals get 
progressivel
y longer, the subjec t should undergo continuous ECG monitoring.  A 
cardiologist should be consulted if QTcF intervals do not return to less than 500 msec (or 
to <45 msec above the baseline) after 8 hours of monitoring (or sooner, at the discretion 
of the investigator).
Furthe r ECG monitoring will occur if a) a post -dose QTcFinterval is increased by  
30msec from the baseline andis>450 msec; or b) an absolute QTcF value is 
500msec for an y scheduled ECG . If either of these conditions occurs, then 2 additional 
ECGs will be collected approximately  2to 4minutes apart to confirm the original 
measurement. If the QTc Fvalues from these repeated ECGs remains above the threshold 
value, then a single ECG must be repeated at least hourly  until QTc Fvalues from 
2successive ECGs fall below the threshold value that triggered the repeat measurement.
In some cases, it may be appropriate to repeat abnormal 12 -lead ECGs to rule out improper 
lead placement as contributing to the ECG abnormality .  It is important that leads are placed 
in the same positions each time in order to achieve precise ECG recordings.  If a 
machine -read QTcF value is prolonged, as defined above, repeat measurements may  not be 
necessary  if a qualified phy sician’s interpretation determines that the QTc Fvalues are in the 
acceptable range.
ECG data will be submitted to a central laboratory for overread measurement of ECG 
intervals and overall interpretation.   The central ECG laboratory will be blinded to treatment 
allocation.  The final ECG report from the central labor atory should be maintained in the 
subject’s source documentation and be the final interpretation of the ECG recording.  An y 
clinically significant changes from the Baseline/Day 1 ECG may  potentially  be adverse 
events (AEs) ( Section 8.2) and evaluated further, as clinically warranted.
7.2.Pharmacokinetics
7.2.1. Plasma for Analysis of PF -06865571
Blood samples ( approximately  4mL) to provide a sufficient amount of plasma for PK
analysis will be collected into appropriatel y labeled tubes containing dipotassium 
ethylenediaminetetraacetic acid (K 2EDTA) at times specified in the Schedule of Activitie s
section of the protocol. 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 46PK sampling time points in this study may be adjusted to adequately assess the plasma PK 
profile based on emerging data.  The actual times may change, but the number of samples will remain the same.  All efforts will be made to obtain the PK samples at the exact nominal time relative to dosing.  However, samples obtained within 2 hours of the nominal time from dosing will not be captured as a protocol deviation, as long as the exact time of the sample collection is noted on the source document and data collection tool (eg, CRF). 
Samples will be analyzed using a validated analytical method in compliance with Pfizer 
standard operating procedures (SOPs).
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity.  Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor.  On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.  Any deviation from the specified sample handling procedure resulting in compromised sample integrity will be considered a protocol deviation.
As part of understanding the PK of the IP, samples may be used for metabolite identification 
and/or evaluation of the bioanalytical method,  
  These data will not be included in the CSR. 
 
 
 
 CCI
CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 47CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 48CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 497.5. Imaging Assessments 
7.5.1. Assessment of Liver Fat and Stiffness Using FibroScan®®
In this study, estimation of liver fat and stiffness using FibroScan®will occur at scheduled
visits outlined in the Schedule of Activities .  Each acquisition will take approximately 
10 minutes and requires the subject to be in a supine position with the right arm placed flat above the head.  Acquisition results do not
need independent over-read, but steps to ensure 
the acquisition was complete and accurate are required, as per training to be provided by EchoSens (vendor supporting the device) at the start of the study.  As much as practically 
possible , attempts will be made to ensure each individual subjects’ assessment is performed 
by the same operator.  All FibroScan®operators will be trained and certified by EchoSens, 
and must be a sonographer or comparable.
Complete details regarding acquisitions using FibroScan®to assess liver fat by CAPTMand 
LSM will be provided by EchoSens before initiation of this study. All images acquired must be saved by the study site until the conclusion of the study; the summary of numerical results (including quality-related outputs) must be printed and saved by the study site (or Imaging facility, as applicable) as part of each subject’s source documents. 
The FibroScan
®is performed on the right lobe of the liver through intercostal spaces via a
transducer probe that delivers a painless, mechanical impulse to the liver and measures the 
resulting shear wave. The LSM is directly proportional to the velocity of the shear wave.  Simultaneously, the CAP
TMmeasures the ultrasonic attenuation coefficient in the forward 
and return path of the radio-frequency pulse through the liver.  The device calculates the median LSM and liver fat values by CAP
TMafter a total of 10 valid, serial measurements are 
acquired per assessment.  
7.5.2. Assessment of Liver Fat Using MRI-PDFF Acquisition and Analysis
At scheduled visits (refer to the Schedule of Activities ), liver fat will be assessed via MRI, 
using the PDFF acquisition protocol. 
Across the study sites selected for this study, the Sponsor-identified central imaging vendor 
will train the staff at the Imaging facility on the MRI-PDFF acquisition protocol, on real time review of image quality and readability of the acquired images, and on transfer (preferably electronically) of the images to the Sponsor-identified central imaging vendor for analysis and quantification of liver fat.  Only
the staff members at the Imaging facility who are 
trained by the Sponsor-identified central imaging vendor are permitted to acquire 
images in the subjects who consent for this study, however in rare/limited situations, 
exceptions may be granted with written approval of the Sponsor.  Complete details on the MRI-PDFF acquisition protocol, determination of quality of images, and transmission of data CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 50to Sponsor -identified central imaging vendor will be provided in an Imaging Manual offered 
to the study  sites prior to the start of the study .
As much as practically possible , analy sis of the MRI -PDFF images acquired from baseline 
(Day -
2) to end of treatment will be undertaken by a single colleague at the 
Sponsor -identified central ima ging vendor who will be blinded to individual subject’s
clinical data, a s well as randomization and stratification assignment . 
The baseline (Day  -2) assessment for MRI -PDFF should be at approximately the same clock 
time (ie ,within a practical window ( 2hours) relative to clock time of the screening visit) .  
All post -dose assessments for MRI -PDFF should occur within a practical window (2hours) 
relative to clock time of the baseline assessment.
7.5.3. Analysis of MRI -PDFF Images Including Determination of Eligi bility 
A subject’s eligibility  for this study  based on liver fat as assessed via MRI -PDFF at Screen 
3will be made b y the Sponsor -identified central imaging vendor, only.  The individual 
subject’s liver fat will not be communicated to the study  site, only the stratum to which the 
subject is assigned.  In the case of the MRI at Screen 3, study  sites will only be informed 
whether a subject meets eligibility  criteria orif the screening MRI should be repeated once, 
as determined b y the Sponsor -identified cent ral imaging vendor.  For allsubsequently  
scheduled MRI -PDFF assessments, study  sites will only be informed whether the images are 
deemed evaluable (or not).  Of note, subjects with non -evaluable baseline images (as 
determined b y the Sponsor -identified central imaging vendor) may be withdrawn prior to or 
after randomization, at the discretion of the Sponsor . 
7.5.4. Management of Incidental Findings
An incidental finding is one unknown to the subject that has potential health or reproductive 
importance, which is d iscovered unexpectedl y in the course of a research study , but is 
unrelated to the purpose and bey ond the aims of the study .
The MRI images will be reviewed by  a Sponsor -identified central imaging vendor .  The 
purpose of this review is to evaluate images fo r the amount of fat in the liver . Central image 
review is not a complete medical review of the subject.  If, during the central review process, 
an unexpected observation is identified and this finding could, in the opinion of the central 
reviewer, have a significant health or reproductive consequence, this finding may  be shared 
with the study  sponsor for disclosure to the principal investigator.  All follow -up testing and 
final diagnosis will be left to the discretion of the medical professionals at the si te or those 
with an existing phy sician -patient relationship.  The principal investigator will be responsible 
for reporting an y AEs identified from incidental findings as described in the ADVERSE 
EVENT REPO RTING section .  Identific ation of such incidental findings during the central 
review process should not be expected, and the site maintains responsibility  for performing a 
general safet y review of all images as per study  site protocols. 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 517.5.5. Post-hoc Analyses
   
 
  Any such 
analyses will not be included in the CSR; but a separate supplemental report will be written to capture this work, if undertaken.
7.6. Potential Cases of Acute Kidney Injury
Abnormal values in serum creatinine (SCr) concurrent with presence or absence of increase 
in blood urea nitrogen (BUN ) that meet the criteria below, in the absence of other causes of kidney injury, are considered potential cases of acute kidney injury and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5μmol/L) in SCr level relative to the subject’s own 
baseline measurement should trigger another assessment of SCr as soon as practically feasible, preferably within 48 hours from awareness.
If the second (repeat) result is still increased by ≥0.3 mg/dL (or ≥26.5μmol/L) relative to the 
subject’s own baseline, assessment of eGFR using serum cystatin C should be performed.  
Based on these measurements, eGFR using SCr and serum cystatin C will be determined and reviewed, preferably within 72 hours, and not later than 96 hours from the confirmed (repeat) elevated SCr result.
If an individual subject demonstrates CONCOMITANT SCr-based AND serum cystatin 
C-based eGFR decline of ≥30% compared to the subject’s baseline eGFR, then the subject 
should not be further dosed and adequate, immediate, supportive measures and treatment as clinically indicated.  Referral to a nephrologist (preferably within 24 hours) is also recommended.  If the subject cannot be seen by a nephrologist within 24 hours (as described above), then the subject may be sent to a local emergency room for evaluation and treatment as clinically indicated. Results should be repeated weekly or as indicated until the renal parameters are deemed to be stable by the nephrologist and/or PI.
Subjects should return to the investigator site and be evaluated as soon as possible, preferably 
within 48 hours from awareness of the second assessment confirming abnormal eGFR result.  This evaluation should include laboratory tests, detailed history, and physical assessment.  In addition to repeating SCr, laboratory tests should include serum BUN, serum creatine kinase, and serum electrolytes (including at a minimum potassium, sodium, phosphate/phosphorus, and calcium), in addition to urinary dipstick, urine microscopic examination, and urinary indices.  All cases confirmed on repeat testing as meeting the laboratory criteria for acute kidney injury, with no other cause(s) of laboratory abnormalities identified, should be considered potential cases of drug-induced kidney injury irrespective of availability of all the results of the investigations performed to determine etiology of the abnormal SCr.  CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 527.7. Blood Volume
The total blood sampling volume for individual subjects in this study  is approximately  
390mL.  The actual collection times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessments at times specified by Pfizer, provided the total 
volume taken during the study does not exceed 550 mLduring an y period of 60 consecutive 
days.
8.ADVERSE EVENT REPO RTING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 types of events: (1) SAEs; 
(2)non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study  during pregnancy  or breastfeeding, and occupational exposure. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Non-serious AE All None
Exposure to the 
investigational product under 
study  during pregnancy  or 
breastfeeding, and 
occupational exposureAll (regardless of whether 
associated with an AE), 
except occupational 
exposureExposure during pregnancy , 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety  on the CT SAE Report 
Form within 24 hours of awareness of the event by the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespectiv e of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 53For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may  be 
requested b y Pfizer Safety to obtain specific follow -up in formation in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent deter mination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to Pfize r Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conduct ed by the sponsor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clar ity and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Rep
ort Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term shoul d be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneousl y 
reported b y the stud y subject .  In addit ion, each study  subject will be questioned about the 
occurrence of AEs in a non -leading manner.
8.1.3. Withdrawal From the Study Due to Adverse Events (see also the Subject 
Withdrawal section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 548.1.4. Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed consent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  
study -related procedure and/or receiving investigational product), through and including a 
minimum of 28 calendar daysafter the last administration of the investigational product.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the ac tive collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that th e 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be pr ovided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the de termination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not kno w whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality
 assessment is “unknown but not 
related ” to investigational product, this should be clearl y documented on study  records. 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 55In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source documents an d CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious a dverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a ca usal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medicat ion error;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 56Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other th erapy; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  Any abnormal test result that is determined to be an error doe s not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of exi sting hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly/birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that t he event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 57Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dy scrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
8.2.4. Hospitalization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary care unit, or neurologi cal floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospitalization does not include the following:
Rehabi litation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include: 
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pr etreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a study  (eg, for a procedure required by  the study  
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 58Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reporte d if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
8.3.Severity Asses sment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfe re with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug- induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) a nd/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated wi thin the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 59are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of he molysis and an alkaline phosphatase value 
<2×ULN or not available.
For subjects with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are ab ove the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increas ed from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncert ainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal re sults.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment.  
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutamy l 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as r eview of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 60collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliar y tract) may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet b een found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirm ed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.2. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational p roduct under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.2.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposu re during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pr egnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been e xposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.   In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 61Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the terminated fetus should be assessed by  gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenital anomal y and t he findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterin e fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and miss ed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or pos sibly  related to 
exposure to the investigational product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject wa s given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.2.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use. However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.2.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 62An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.4.3. Medication Errors 
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE) Only  if associated with an 
SAE 
8.4.3.1. Medication Errors
Medication errors may  result from the administration or consumption of the investig ational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength .
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is for eseen in the protocol that do 
or do not involve the participating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, a ny associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 639. DATA ANALYSIS/STATISTICAL METHODS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by the sponsor.  The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Sample Size Determination
Approximately 15 subjects per arm are planned in this study for a total of approximately 
45 subjects.  Assuming an approximate 5% premature withdrawal rate, this will ensure a minimum of 42 subjects complete the study.  With this sample size the power to detect a 25% mean reduction in MRI-PDFF relative to placebo is at least 79% using a 1-sided Type I error rate of 0.1.  This calculation assumes the pooled SD of the log-relative change of 0.36 (based on an internal study).
9.2. Efficacy Analysis
The primary analysis population for all efficacy analyses will include all randomized subjects 
who received at least 1 dose of study medication (Full Analysis set). 
9.2.1. Analysis of the Primary Endpoint 
The primary endpoint will be the relative change from baseline at Day 15 in whole liver 
PDFF.  Baseline will be the closest measurement prior to first dose on Day 1.  An analysis of covariance (ANCOVA) will be performed on log-transformed relative change with treatment and baseline diabetic status as factors, log-transformed baseline whole liver PDFF value as a covariate. Estimates of the mean relative changes between each active dose and placebo at Day 15, and the corresponding 80% confidence interval (CI) will be obtained from the model.  Each comparison of PF-06 865571 dose with the p lacebo will be performed at a Type I
error rate of 10% (1-sided). No adjustment for multiple comparisons will be made. If the model does not fit the data group medians and their differences from the placebo median will be presented.  The details will be provided in the SAP.
Descriptive summaries of the observed values and percent change from baseline in whole 
liver PDFF for each treatment group will also be produced.
 
 
 
 
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 649.3. Pharmacokinetic Analysis
The PK concentration population will be defined as all randomized subjects who received at 
least 1 dose of PF-06865571 and in whom at least 1 plasma PK concentration value is reported.  The PK parameter analysis population will be defined as all randomized subjects who received at least 1 dose of PF-06865571 and who have at least 1 of the PK parameters of interest calculated.  PK samples from placebo samples will not be routinely analyzed.
9.3.1. Derivation of Pharmacokinetic Parameters
The PK parameters for PF-06865571 will be derived from the concentration-time profiles as 
data permit.  The various PK parameters to be assessed in this study, their definition and method of determination are outlined in Table 7.  Actual PK sampling times will be used in the derivation of PK parameters.
Table 7. Definition of Steady State (Day 14) Plasma PK 
Parameters for PF-06865571
Parameter Definition Method of Determination
AUC tau Area under the plasma 
concentration-time profile from 
time zero to time tau ( τ), the 
dosing intervalLinear/Log trapezoidal 
method
Cmax Maximum plasma 
concentration during the dosing 
intervalObserved directly from data
Tmax Time for C max Observed directly from data 
as time of first occurrence
CL/F Apparent clearance Dose/AUC tau
Cmin Minimum plasma concentration during the dosing intervalObserved directly from data
PTR Peak-to-trough ratio C max/Cmin
The above listed PK parameters will be summarized descriptively by dose. Relationships 
between PF-06865571 PK and safety and/or efficacy endpoints may also be explored, but may not be included in the final CSR.
 
 
 
 
 
 
 CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 65 
 
 
 
9.6. Safety Analysis
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of subjects.  Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described.  Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination information collected during the course of the 
study will be considered source data and will not be required to be reported, unless otherwise noted.  However, any untoward findings identified on physical examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted.  Demographic data collected at screening will be reported.
9.6.1. Electrocardiogram Analysis
Changes from baseline for the ECG parameters QT interval, heart rate, QTcF interval, PR 
interval, and QRS interval will be summarized by treatment and time.
The number (%) of subjects with maximum postdose QTcF values and maximum increases 
from baseline in the following categories will be tabulated by treatment: 
Safety QTcF Assessment
Borderline (msec) Prolonged (msec)
Absolute value ≥450 - <480 ≥480
Absolute change 30-<60 ≥60
In addition, the number of subjects with corrected and uncorrected QT values ≥500 msec will 
be listed.
In addition, an attempt will be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach.  If a PK/PD relationship is found, the impact of subject factors (covariates) on the relationship will be examined.  The analysis, if conducted, may not be reported.CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 669.7. Interim Analysis 
Interim anal yses may  be performed to assess efficacy  and/or safet y after at least 50% of the 
planned subjects, ie, approximately  21subjects, complete the study .Interim analy sis results 
may be used for internal business decisions regarding future study
 planning, stopping for 
futility , conducting a sample size reestimation, or adapting the study  after the interim 
analysis.Before an y interim analysis is instigated, the details of the objectives, decision 
criteria, dissemination plan ,and method of maintaining the study  blind as per Pfizer’s SOPs 
will be documented and approved in a ninternal review committee (I RC) charter.  In additi on, 
the anal ysis details willbe documented and approved in an interim anal ysis SAP or final 
SAP.
9.8.Data Monitoring Committee 
This study  will not use a data monitoring committee (DMC ).This study  will potentially  use 
an IRC comprised of Pfizer employ ees (or designees) who are not directly  involved in the 
day-to-day conduct of the study .  
If an IRC is used then an IRC charter will be developed to 
govern the details of the interim anal ysis and IRC operations .
10.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or it s agent will conduct periodic monitoring visits during study  conduct for studies 
conducted at non- Pfizer investigator sites,to ensure that the protocol and Good Clinical 
Practices ( GCPs) are being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs are accurate.  T he investigator and institution will 
allow Pfizer monitors/auditors or its agents and appropriate regulatory  authorities direct 
access to source documents to perform this verification.  This verification may also occur 
after stud y completion.
During study  conduct and/or after study  completion, t
he investigator site may  be subject to 
review b y the IRB/EC , and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by  appropriate regulatory  
authorities.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with Pfizer 
orits agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection. The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the study  
data and the subject’s medical records.  The investigator will promptly  provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or i ts agents with an opportunity  to review 
and comment on responses to any  such findings.
For studies conducted at non -Pfizer investigator sites, it is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process. 

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 6711.DATA HANDLING AND RE CORD KEEPING
11.1. Case Report Forms/ Data Collection Tools/ Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRFis required and should be completed for each included subject.  The completed 
original CRFsare the sole propert y of Pfizer and should not be made available in any  form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory  
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and reportin g of all clinical, 
safet y,and laboratory  data entered on the CRFsand any  other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, attributable, complete, 
consistent, legible, timely  (contemporaneous), endurin g,and available when required.  The 
CRFsmust be signed by  the investigator or by  an authorized staff member to attest that the 
data contained on the CRFs are true.  An y corrections to entries made in the CRFs orsource 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry .
In most cases the source documents are the hospital or the ph ysician's chart.  I n these cases, 
data collected on the CRFsmust match those charts. 
In some cases, the CRF may also serve a s the source document.  In these cases, a document 
should be available at the investigat orsite 
andat Pfizer that clearl y identifies those data that 
will be recorded on the CRFand for which the CRFwill stand as the source document.
11.2. Record Retention
To en able evaluations and/or 
inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, e g,CRFsand hospital records), all original signed 
informed consent documents, copies of all CRFs ,safet y reporting forms, source documents, 
detailed records of treatment disposition, and adequate documentation of relevant 
correspondence (e g,letters, meeting minutes, and telephone call reports ).  The records should 
be retained b y the investigator according to the ICHguidelines, according to local 
regulations, or as specified in the clinical study  agreement (CSA) , whichever is longer.
If the investigator becomes unable for an y reason to continu e to retain study records for the 
required period (e g,retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer, such as another 
investigator, another institution, or to an independent third part y arranged by Pfizer. 
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study
 or for longer if required by applicable local regulations.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 68The investigator must obtain Pfizer's writ ten permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amend ments, informed consent documents, and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator file .  Copies of I RB/EC approvals should be 
forwarde d to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, andthe general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH G uideline for Good C linical Practice , and the Declaration of 
Helsinki.
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where 
required b y laws. 
When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
names, address es, and other identifiable data will be replaced b ynumerical code sbased on a 
numbering sy stem provided by  Pfizer in order to de -identify  study subjects .The investigator 
site will maintain a confidential list of subjects who participate d in the study ,linking each 
subject’ snumerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws .
The informed consent document sand an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .
The informed consent document sused during the informed consent pro cess and an y subject 
recruitment materials 
must be reviewed and approved by  Pfizer , approved by  the IRB/EC
before use , and available for inspection.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 69The investigator must ensure that each study  subject , is fully  informed about the nature and 
objectives of the study  and possible risks associated with participation. 
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject before any  study -specific activity  is performed.  The investigator 
will retain the original of each subject's signed consent document.
12.4. Reporting of S
afety Issues and S erious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any  area of the world , or if the investigator is aware of any  new 
information that 
might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately. 
In addition, the investigator will inform Pfizer imm ediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End o f Trial in the United States
Last subject last visit ( LSLV)is defined as the date the investigator reviews the last subject’s 
final safet y data and determines that no further evaluation is required for the subject to 
complete the trial.
14. SPONSOR DISCONTINU ATION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC, or investigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
PF-06865571 at any  time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 7 days.  As directed by  Pfizer, all study  materials must be collected and 
all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinic al 
study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov) , the European Clinical Trials 
Database (EudraCT), and/or 
www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 70www.clinicaltrials.gov
Pfizer posts clinical trial US B asic Results on www.clinicaltrials.gov for Pfizer- sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study is conducted.   US 
Basic Results are submitted for posting within 1 year of the primary  completion date 
(PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was exami ned or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study
concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 y ear of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric popula tions.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual patients have been removed) on www.pfizer.com for Pfizer- sponsored 
interventional studies at the same time the US Basic Results document is posted to 
www.clinicaltrials.gov .
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  the
principal investigator (PI)of the results of the study  based on information co llected or 
generated b y thePI, whether or not the results are favorable to the Pfizer product.
  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the i nvestigator will provide Pfizer an opportunity  toreview any  proposed 
publication or other t ype of disclosure of the results of the study  (collectively , “publication”)
before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at least 30 days before 
it issubm itted 
for publication or otherwise disclosed.  If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 days.
The i nvestigator will, on request, re move any  previously  undisclosed confidential 
information before disclosure, except for an y study -or Pfizer product -related information 
necessary  to the appropriate scientific presentation or understanding of the study  results .

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 71If the study  is part of a mu lti center study , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publications 
by the 
PIwill reference that primary  publication.  However, if a joint manuscript has no t 
been submitted for publication within 12 months of completion or termination of the study  at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this section .
For all publications relating to the study , the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to B iomedical Journals, 
http://www.icmje.org/index.html#authorship,
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the C SAbetween Pfizer and the 
institution.  I n this section entitle d Publications by  Investigators , the defined terms shall have 
the meanings given to them in the C SA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict betwe en this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will control as to all other 
issues.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 7216.REFERENCES
1. Yen CL , Stone SJ, Koliwad S, et al.  Thematic review series: gl ycerolipids. DGAT 
enzymes and triacy lglycerol biosynthesis.  J L ipid Res 2008;49(11):2283- 301.
2. Buhman KK, Smith SJ, Stone SJ, et al.  DGAT1 is not essential for intestinal 
triacy lglycerol absorption or ch ylomicron s ynthesis.  J Biol Chem 
2002;277(28):25474-9.
3. Cases S, Stone S J, Zhou P, et al.  Cloning of DGAT2, a second mammalian 
diacy lglycerol acy ltransferase, and related family  members.  J Biol Chem 
2001;276(42):38870-6.
4. Choi CS, Savage DB .Suppression of diacy lglycerol acy ltransferase -2 (DGAT2), but 
not DGAT1, with antisen se oligonucleotides reverses diet- induced hepatic steatosis and 
insulin resistance. J Biol Chem 2007;282(31):22678
-88.
5. Yu XX, Murray  SF, Pandey  SK, et al.  Antisense oligonucleotide reduction of DGAT2 
expression improves hepatic steatosis and h yperlipidemi a in obese mice.  Hepatolog y 
2005;42(2):362 -71.
6. Liu Y, Millar JS, Cromley  DA, et al.  Knockdown of acy l-CoA:diacy lglycerol 
acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion 
in mice.  Biochim Biophys Acta 2008;1781(3):97 -104.
7. Fon Tacer K, Rozman D. Nonalcoholic fatt y liver disease: focus on lip oprotein and lipid 
deregulation. J Lipids 2011; 1-14.
8. Marchesini MB, Bi anchi G, et al. Nonalcoholic fatty  liver disease: a feature of the 
metabolic s yndrome. Diabetes, 2001;50(8): 1844- 50.
9. Hass JT, Francque S, Staels B. Pathophy siology  and mechanisms of nonalcoholic fatty  
liver disease. Ann Rev Phy siol 2016;78: 181-205.
10. Sany al AJ, Friedman SL , McCullough AJ, et al. Challenges and opportunities in drug 
and biomarker development for nona lcoholic steatohepatitis: findings and 
recommendations from an American Association for the Study  of L iver Diseases -U.S. 
Food and Drug Administration Joint Workshop.  Hepatolog y2015;61(4):1392 -
405.
11. Cohen JC, Horton JD, Hobbs HH. Human fatt y liver disease: old questions and new 
insights. Science 2011;332(6037): 1519-23.
12.
Sanders FWB, Griffin JL.De novo lipogenesis in the liver in health and disease: more 
than just a shunting y ard for glucose. Biol Rev 2016;91: 452-68.
13. Lambert JE, Ramos -Roman MA. Increased d e novo lipogenesis is a distinct 
characteristic of individuals with nonalcoholic fatty  liver disease. 
Gastroenterology  
2014;146 (3): 726-35.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 7314. Noureddin M, Lam J, Peterson MR, et al.  Utility  of magnetic resonance imaging versus 
histology  for quantify ing chan ges in liver fat in nonalcoholic fatt y liver disease trials.  
Hepatolog y 2013;58:1930-40.
15. Le TA, Chen J, Chanqchien C, et al.  Effect of colesevelam on liver fat quantified by 
magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled tria l. 
Hepatolog y 2012;56:922-32.   
16. Loomba R, Sirlin CB, Ang B, et al.  Ezetimibe for the treatment of nonalcoholic 
steatohepatitis: assessment by  novel magnetic resonance imaging and magnetic 
resonance elastograph y in a randomized trial (MOZART Trial). Hepat ology  
2015;61:1239-50.
17. Motohashi H, I nui K. Organic cation transporter OCTs (SL C22) and MATEs (SL C47) 
in human kidney . AAPS J 2013; 15(2): 581-8.
18.
Inker LA, Schmid CH, Tighiouart H, et al. Estimating Glomerular Filtration Rate from 
Serum Creatinine and C ystatin C. N Engl J Med 2012; 367:20-9.
19. Pischon T, Girman CJ, Sacks FM, et al. Non-high-density  lipoprotein cholesterol and 
apolipoprotein B in the prediction of coronary  heart disease in men. Circulation 2005; 
112(22): 3375-83.
20. Rhainds D, Arsenault BJ, Tardif JC.  PCSK9 inhibition and L
DL cholesterol lowering: 
the biology  of an attractive therapeutic target and critical review of the latest clinical 
trials.  Clin L ipidol 2012:7(6):621 -40.

PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 74Appendix 1. Abbreviations 
The following is a list of abbreviations that may be used in the protocol.   
Abbreviation Term
A1AT α-1-antitrypsin
Abs absolute
AE adverse event
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
AUC area under the curve
BA bioavailability
BBS Biospecimen Banking System
BCRP breast cancer resistance protein
BE bioequivalence
BID twice daily
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CAP controlled attenuation parameter
CFB change from baseline
CI confidence interval
CK creatine kinase
CLr renal clearance
Cmax maximum observed concentration
Cmin minimum concentration
CO2 carbon dioxide (bicarbonate)
CRF case report form
CRU clinical research unit
CSA clinical study agreement
CSF cerebrospinal fluid
CSR clinical study report
CT clinical trial
CTA clinical trial application
CTCAE Common Terminology Criteria for Adverse Events
CYP450 cytochrome P450
DAG diacylglycerol
DDI drug-drug interaction
DGAT diacylglycerol acyltransferase
DILI drug-induced liver injury
DMC data monitoring committeeCCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 75Abbreviation Term
DNL de novo lipogenesis
DPP-4 dipeptidyl peptidase-4
DU dispensable unit
EC ethics committee
ECG electrocardiogram
E-DMC external data monitoring committee 
EDP exposure during pregnancy
EDR extemporaneous dispensing record
EDTA edetic acid (ethylenediaminetetraacetic acid)
eGFR estimated glomerular filtration rate
EU European Union
EudraCT European Clinical Trials Database
FA fatty acids
FFA free fatty acids
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
H hour(s)
HbA1c hemoglobin A1c
HBV hepatitis B virus
hCG human chorionic gonadotropin
HCV hepatitis C virus
HepBcAb hepatitis B core antibody
HepBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
IB investigator’s brochure
ICD informed consent document
ICH International Conference on Harmonisation
ID identification
IND investigational new drug
INR international normalized ratio
IP investigational product 
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IV intravenous
IWR interactive Web-based responseCCI
CCI
CCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 76Abbreviation Term
K2EDTA dipotassium ethylenediaminetetraacetic acid
kPa kilopascal
LDL-C low density lipoprotein cholesterol
LFT liver function test
LLN lower limit of normal
LSLV last subject last visit 
MATE multi-drug and toxin extrusion protein
mBCRP mouse breast cancer resistant protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR1 multi-drug resistance protein 1
MDRD modification of diet in renal disease equation
MELD model of end-stage liver disease
MGAT monoacylglycerol acyltransferase
MMRM mixed model for repeated measures 
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
N/A not applicable
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NOAEL no observed adverse effect level
NSAIDs non-steroidal anti-inflammatory medications
NYHA New York Heart Association
OAT organic anion transporter
OATP organic anion transporter polypeptide
OCT organic cation transporter
PBPK physiologically based pharmacokinetic
PCD primary completion date
PCSK9 proprotein convertase subtilisin/kexin type 9
PD pharmacodynamic(s)
PDFF proton density fat fraction
P-gp P-glycoprotein
pH potential of hydrogen
PI principal investigator
PIB powder in bottle
PK pharmacokinetic(s)
PT prothrombin time
PTR peak to trough ratio
Q8H every 8 hours
Q12H every 12 hoursCCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 77Abbreviation Term
QTc corrected QT interval
qual qualitative
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SCr serum creatinine
SD standard deviation
SOP standard operating procedure
SRSD single reference safety document
t1/2 Half-life
TBili total bilirubin
T2DM type 2 diabetes mellitus
TG triglycerides
THC tetrahydrocannabinol
Tmax time to reach maximum concentration
UDP uridine diphosphate
UGT uridine diphosphate glucuronosyltransferase
ULN upper limit of normal
US United States
VLDL very low density lipoprotein
WBC white blood cellCCI
PF-06865571 
C2541005
Final Protocol, 27 February 2018
Page 78Appendix 2.Strong CYP3A Inhibitors and Inducers *
CYP 3A Inhibitors CYP 3A Inducers
HIV antivirals HIV antivirals
Indinavir Nevirapine
Nelfinavir Miscellaneous
Ritonavir Barbiturates
Saquinavir Carbamazepine
Boceprevir Glucocorticoids (systemic)
Lopinavir/ritonavir Oxcarbazepine
Amprenavir Phenobarbital
Atazanavir Phenytoin
Telaprevir Rifabutin
Darunavir/ritonavir Rifampin
Fosamprenavir St. John's wort3
Tiprinavir/ritonavir Troglitazone
Antibiotics Nafcillin
Clarithromycin Avasimibe4
Troleandomycin Enzalutamide
Telithromycin Mitotane
Anti -infectives
Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Miscellaneous
Nefazodone
Grapefruit juice1
Conivaptan
Mibefradil2
Idelalisib
1.The effect of grapefru it juice varies widely among brands and is concentration -, dose- , and preparation -
dependent.  Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain 
preparation w as used (eg, high dose, double strength) or as a “moderate CYP3A inhibitor” when another 
preparation w as used (eg, low  dose, single strength).
2.Withdrawn from the United States market.
3.The effect of St. John’s wort varies w idely and is preparation -dependent.
4.Not a marketed drug.
* This list is not considered as exhaustive.   Any  questions regarding use of CYP3A inhibitors and inducers 
should be directed to the Sponsor study team.
Reference: U.S. Food and Drug Administration.  Drug Development and Drug Interactions: 
Table of Substrates, Inhibitors and Inducers, a vailable at : 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Drug Inter
actionsLabeling/ucm093664.htm
